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Abstract
Cancer is one of the world’s foremost causes of death, affecting over 15 million people.
While traditional therapies offer some efficacy to patients novel treatments are needed
to combat this epidemic. In recent years, novel immune- and combination-therapies have
shown great strides in easing the cancer burden for some patients. One of these novel
treatment modalities is oncolytic virotherapy, a form of immunotherapy which uses
viruses with an inherent tumor specific tropism. Oncolytic virotherapy is an attractive
option due to both its inherent immunotherapeutic potential as well as the ease by which
it can be combined with other treatment modalities. Here, we studied both advantages
using two tumor models which each pose a unique therapeutic challenge. First, we used
a combination strategy including oncolytic Myxoma virus and traditional standard of care
to treat glioblastoma multiforme. The results of this study showed that standard of care
increased the spread of oncolytic virus both in vitro and ex vivo resulting in a synergistic
therapeutic effect. Taken together these data suggests that this would be an effective
combination for translation in vivo. Secondly, we sought to increase the spread of the
oncolytic virus as a means to increase overall efficacy. By adding the fusion protein from
a variety of other viruses into oncolytic myxoma virus we were able to produce a group
of fusogenic constructs which induced syncytia formation during infection. Surprisingly,
while these constructs looked promising in vitro, they displayed decreased efficacy in vivo
negatively correlated to the viruses ability to form syncytia. These studies show the
potential which myxoma has in synergizing with current therapeutic options, while also
raising the question as to why some combinations may fail in vivo.
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Introduction
Cancer is a chronic disease associated with cellular division which is no longer
controlled by the proper cell-cycle checkpoints. This lack of control leads to cells which
can divide without the assurance of genetic integrity1. In addition, most cancers possess
the unique ability to ward off detection by the host immune system so that the tumor
may grow unhindered2-4. This combination of the tumor being able to grow uncontrollably
while also preventing the immune system from eliminating the malignancy has led to
cancer become a global epidemic5.
In addition to cancer’s growth and immune-resistant nature, another major issues
stems from the vast majority of tissues which can be affected. This phenomenon has
partially led to the inherent difficulty which researchers and medical professionals have
had in treating malignancies. With each tumor stemming for a different cell of origin, and
subsequently possessing a unique cell line specific phenotype, it is improbable that a
single treatment will work for the majority of tumor populations.
Traditional cancer therapies generally consists of several components: surgical
resection, radiation and chemotherapy. Surgical resection of a tumor involves the
removal of the majority of the tumor mass. While this form of therapy is very effective
for the majority of localized tumors if the tumor has become too large, diffuse with the
surrounding tissue or has undergone metastasis surgery provides no added efficacy. As
such, surgical resection is generally reserved for use with early diagnoses as a means to
prevent the progression of the tumor. Radiation therapy targets the DNA of cells,
resulting in double strand breaks (DSB) which activates a DNA damage pathway and
ultimately cellular death in some tumor lines which lack the proper mechanisms to deal
with such damage6-8. While radiation therapy offers more tumor specificity than that of
surgical resection, it is also associated with moderate levels of toxicity in the patient.
Additionally, not all tumor cells have a defect in DNA repair machinery and will not
respond to this form of treatment. Finally, chemotherapy is the use of a vast library of
cytotoxic drugs which target various aspects of the tumor phenotype which results in
death of the cancer cells9. While chemotherapeutics have seen promising levels of
efficacy in some patients, many patients see little improvement due to the constantly
changing tumor phenotype and tumor heterogeneity and subsequent development of
resistance to the therapeutic agent10, 11. Additionally, chemotherapy is associated with
very high levels of toxicity and severe side effects12, 13. It is because of this that
researchers, as well as medical professionals, have begun to look for novel therapy
options to combat the growing problems associated with traditional cancer treatments.
One such class of therapeutics which has gained significant traction in the past
decade is that of immunotherapy14-16. This form of therapy comprises all treatments
which aim to mount a potent anti-tumor response from the body’s natural immune
system. Included in this field is oncolytic virotherapy (OV)17-22. OV works on the premise
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Figure 1:
Schematic of oncolytic virotherapy. Viruses injected into malignant cells which allow for
viral replication due to a variety of cancer specific defects. Viral progeny will then spread to
neighboring cells before lysing the cell. Once the infected cells have lysed, viral particles and
tumor antigen are released into the tumor microenvironment and are detected by
circulating immune cells. The release of tumor antigen results in the priming of an antitumor T-cell response against the rest of the tumor mass.

that viruses can replicate without interruption in tumor cells due to a particular defect
within these cells18, 22, 23. Once infection occurs, the virus is able to replicate freely in the
cell and eventually cause cellular lysis. This lysis in turn results in the release of both viral
and tumor antigens into the surrounding microenvironment. The release of tumor
antigen triggers a potent anti-tumor response and subsequent clearance of a large
portion of the malignancy (Fig 1)24-26. It is by this process that OV is highly specific to tumor
cells and results in very minimal toxicity. While this form of therapy is attractive in its own
right, OV also allows for transgenes to be inserted into the viral genome. The addition of
these novel transgenes to the viral genome allows for the combination of current
immunotherapies to that of OV. This combination offers the benefit of keeping the
therapeutic transgenes localized to the tumor microenvironment, versus having to supply
them systemically.
OV with multiple viruses has previously been shown to display efficacy in multiple
tumor models22 and has led to one FDA approved viral treatment27. Unfortunately there
are still several problems associated with this form of therapy. Of primary concern is the
inability for oncolytic viruses to effectively spread once injected into the tumor28-30. This
low rate of spread leads to less of the tumor population being lysed and the generation
of a less potent anti-tumor immune response as a result. Additionally, OV is best used for
treatment of a localized tumor where the virus can be directly injected. Despite these
challenges, the use of novel oncolytic viruses and the combination with other forms of
cancer treatment is becoming a promising therapy option for patients;
One potential oncolytic virus is myxoma virus (MYXV). This double stranded DNA
virus is a member of the Poxviridae. MYXV exhibits lethal pathogenicity in European
rabbits. In preclinical models, MYXV has been shown to possess oncolytic potential
against gliomas, leukemia, ovarian cancer and myeloma31-34. MYXV maintains a cancer
specific tropism because it preferentially replicates in cells which lack a functioning INF-β
response. As healthy cells possess this response, the virus shows no pathogenicity in
humans35.
The purpose of this study is to apply novel techniques to oncolytic MYXV, in order
to improve efficacy in. To do this, we first sought to improve efficacy in the context of
treatment for glioblastoma multiforme (GBM), as this particular cancer represents a
2

unique challenge for cancer therapy. By adding MXYV to traditional standard of care (SOC)
for GBM we predicted that these two therapeutic modalities would synergize due to the
degree of specificity which each has towards different cell lineages of GBM. Additionally,
because of the cell death associated with GBM SOC we believe that this would offer a
second level of synergy in terms of aiding in the mounting of an adaptive immune
response. We then hoped to find a means to deliver this combination therapy to a
physiologically relevant tumor model using an Alzet osmotic pump. Secondly, we sought
to increase overall efficacy of MYXV as an oncolytic agent by improving the poor spread
associated with these oncolytic viruses. By introducing novel fusion proteins into the
MYXV genome we hoped to increase both spread and cellular death by forcing the
formation of syncytia. This cellular fusion, we believed, would result in inclusion of much
more of the heterogeneous tumor population resulting in a more robust anti-tumor
immune response in vivo.
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Glioblastoma Multiforme: Background and Current Approaches
Glioblastoma (GBM) is a form of cancer which arises from the glial cells of the
brain and is characterized by aggressive spread36. As with many cancers, onset of GBM
occurs later in life with most cases presenting between the ages of 45-75. The disease is
often difficult to diagnosis due to the generality of its symptoms which can include
headaches, nausea and blurred vision. The challenge of a definitive diagnosis of GBM
often leads to disease progression without the patient’s knowledge37, resulting in an
average survival of only 12-36 months after onset following treatment with standard of
care (SOC).
Currently the accepted treatment regimen for GBM focuses on three therapeutic
options; surgery, radiation, and chemotherapeutic drugs38-41. Surgery is often used to
remove the tumor mass, however, this method is typically not sufficient to eliminate all
malignant cells due to their invasion into the normal neural networks42, which would
require the removal of a significant portion of the patient’s brain. This results in the
relapse and reemergence of the tumor.
After surgery patients typically undergo treatment with the chemotherapeutic
drugs Temozolomide (TMZ) or Bevacizumab38,43 in combination with radiation. The
combination of these treatments serves to eliminate what remains of the non-excised
tumor44. TMZ is a DNA alkylating agent, administered orally in an inactive prodrug form45.
The prodrug is then metabolized into the active form which subsequently alkylates the
DNA, frequently on either adenine or guanine46. Unless the proper repair mechanisms are
in place the alkylation will result in cell death during replication and division. Bevacizumab
is a widely used cancer drug which targets the VEGF pathway. Blocking of this pathway
results in limited angiogenesis and decreased survival of the tumor mass due to a loss of
blood flow47. Additionally, blocking of the VEGF pathway has been shown to decrease
cellular proliferation of tumor cells.
Unfortunately, since GBM develops and remains in the brain, it presents a unique
set of therapeutic challenges not commonly associated with other types of cancer48. Both
neurons and glial cells are slow dividing cells which can evade these traditional cancer
treatments which focus on rapid cellular division. An additional challenge lies in the
structure of the cranial cavity which has a minimal volume available. Injections of
chemotherapeutic drugs into this minimal volume can result in increased pressure. This
physiological obstacle frequently prohibits direct injections into the tumor or invasive
surgical operations from being performed. In addition, the blood-brain barrier (BBB),
which acts as a natural barrier between the brain and the rest of the body, presents a
challenge in delivering chemotherapeutic agents to the tumor and prevents many drugs
from being used against GBM49. Due to these therapeutic challenges, GBM prognosis has
remained poor and the disease has become a focus of research to identify novel
treatments which can improve overall patient survival50,51.
As with many other tumor subtypes, immunotherapy has been seen as a novel
treatment option which would drastically increase survival. GBM represents a unique
challenge for immunotherapy because these tumor cells often lack many of the majory
immune markers which make this treatment effective. Commonly excluded from all forms
4

of GBM are CD80 and CD86 receptors, which play crucial roles in T-cell signaling.
Additionally, GBM is characterized as being highly immunosuppressive and limits
traditional immunotherapy options52. Further complicating the matter is the fact that
immunotherapies are often highly inflammatory. In most other tumor models this is not
a concern, but moderate levels of inflammation do not generally pose serious long-term
risks. In GBM, however, the risk of increased inflammation can be life-threatening and
thus has limited the use of immunotherapies to date. In light of these therapeutic
challenges, research has begun to test novel therapies that may provide a safer and more
effective therapy option for patients. However, many of these novel therapy options are
still lacking in some aspect of therapeutic potential and raise the question of the value of
using combination therapies which combine both novel and traditional treatments to
provide a more efficacious outcome.
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Oncolytic Myxoma virus synergizes with standard of care for Glioblastoma Multiforme
Introduction
To date several oncolytic viruses have been previously tested and showed efficacy
in the treatments of GBM53, 54. Early studies into this treatment modality for GBM focused
on the use of HSV as the oncolytic agent. One such study showed the effectiveness of the
virus alone was able to increase overall survival, but also greatly reduced the growth rate
of the tumor both in vivo and in vitro 55. In addition, a novel HSV mutant has been
generated which was highly specific to glioma based tumors. This HSV variant possess a
ICP34.5 gene, responsible for the formation of viral progeny, under control by a nestin
promotor. As nestin is upregulated in gliomas, this virus is highly specific to this cancer
subtype56. Prior to this publication it was shown that HSV also was capable of targeted
infection of the tumor cells leading to the complete eradication of the mass57. These
findings are especially important considering the nature of the GBM tumor. Given that
this tumor grows as a diffuse, rather than a solid, mass the ability to preferentially infect
malignant cells is advantageous from a therapeutic standpoint. One of the most
successful forms of OV for GBM therapy has been those dealing which focus on the use
of HSV thymidine kinases56, 58-62. This gene acts as a suicide gene which results in cellular
death upon infection. Due to the cell cycle dependent nature of the gene, however, the
treatment remains tumor specific. Additionally, in this treatment strategy, an inactive
prodrug is administered which is only activated in the presence of the thymine kinase in
order to ensure an added layer of specificity. This is particularly important for GBM,
because this tumor model is characterized by apoptotic resistance and thus is resistant to
many treatments which rely on cellular death to enhance efficacy.
In addition to HSV, poliovirus was one of the earliest viruses used in the treatment
of GBM. Poliovirus strains used in this study show the a virus with ablated
neuropathogenicity is able to selectively target and eliminate tumors in as little as two
weeks compared to a 45% increase in volume in untreated mice63. Of particular interest
is that this paper demonstrates the mechanism of specificity which allows poliovirus to
target malignant cells, the presence of CD15563,64. The knowledge of this mechanism
allows future studies to generate transgenic viruses with increased specificity for this
receptor and ultimately the tumor. Additionally, it was shown that the virus is cleared
from the brain after the tumor has receded. This is further verified by a decrease in viral
titer which correlated to a decrease in tumor volume65.
Several early studies have also looked at providing additional targeted viral
infection to tumor cells through the use of modified viruses, such as adenovirus (AdV).
Adenovirus is an attractive oncolytic due to its preferential infection of both dividing and
quiescent cells which may better represent the diverse cellular cycle of the tumor cells 66.
One such study using a virus which could only replicate in cells which had a p53 mutation
showed that this form of viral treatment represented a safe therapeutic modality67. The
study goes on to state that the use of this virus resulted in minimal levels of inflammation
compared to HSV studies which showed the possibility of increased inflammation from
the viral infection. While these early studies have focused on laying the foundation for
the use of OV in the treatment of GBM, there are still many questions to be answered on
6

how to increase efficacy of treatment. Recently, research has focused on applying novel
oncolytic viruses in the hopes of increasing overall efficacy.
On such virus which recently has shown efficacy in the treat of GBM is MYXV.
MYXV is an attractive oncolytic candidate due to its inherent ability to specifically infect
tumor cells as well as its non-pathogenic nature towards humans, resulting in an effective
yet safe virus for OV treatment in humans68. Previous studies examining MYXV-based
treatment in GBM models demonstrated a surprising effectiveness in reducing tumor
burden and decreasing cell viability against established tumors in both a mouse69 and
human derived cell lines70. Additionally, it has been shown that a MYXV strain which is
deficient in M011L is able to effectively kill BTICs71. MO11L is responsible for the inhibition
of pathways which trigger apoptosis after the detection of viral infection72. With this gene
removed, the virus no longer can prevent apoptosis from occurring and increases the rate
of death of BTICs without altering the ability of the virus to kill and replicate in
differentiated tumor cells71. This work builds upon a previously study which shows the
BTICs were susceptible to killing through viral infection after treatment with rapamycin69.
While these previous studies are promising they fail to examine how unmodified
MYXV may interact with the current GBM SOC. The first and second specific aims of this
thesis study seek to establish the interaction of GBM SOC and MYXV treatment in the
context of GBM. We first sought to test the hypothesis that MYXV infection would
synergize with GBM SOC to increase efficacy. Previous studies have shown that both
forms of treatment are effective to some extent at treating GBM, but this effectiveness
arises from different mechanisms. Additionally, the tumor microenvironment represents
a highly heterogeneous population of cells which respond differently to each treatment
modality. We believed that the use of two distinct treatment options would therefore
prevent the tumor from gaining therapeutic resistance. This would consequently result in
a more cellular death and allow for a more robust anti-tumor T-cell response. We next
sought to find a safe yet effective means by which to deliver this combination therapy to
the tumor. We hypothesized that the use of an osmotic pump would allow for a
continuous release of both virus and chemotherapeutic to the tumor microenvironment.
The insertion of the pump during surgical resection of the bulk of the tumor mass would
allow for a non-invasive means to provide additional treatment without the need for an
invasive procedure. For the purpose of this section SOC is defined as treatment with 1
Gray (Gy) and treatment with the corresponding chemotherapeutic drug, Temozolomide,
unless otherwise described.
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Results
GBM Standard of Care Increases spread of MYXV
In order to test the efficacy of combining MYXV with the SOC for GBM, we first
looked at how SOC affected the ability of MYXV to establish initial infection, produce new
infectious viral progeny, and spread to neighboring cells. To measure how SOC impacted
initial infection U118 cells, a human GBM cell line, were inoculated with varying MOIs (1,
3, 10) of vGFP in either the presence or absence of radiation (1 Gy) and/or temazolomide.
Infections were allowed to progress for 12 hours after which the initial infection of cells
was determined by analyzing the percent of GFP+ cells using flow cytometry. Not
surprisingly, we observed an increase in GFP+ cells correlated to an increase in MOI.
However, the number of GFP+ cells were not significantly impacted by addition of either
radiation, temazolomide, or SOC (Fig 2A). To analyze the impact of SOC on the production
of new infectious progeny virus, U118 cells were either mock treated or treated with 1 Gy
of radiation and then infected at a MOI of 15. Following infection, cells were treated with
either saline or temazolomide. Samples were harvested at several timepoints post
infection (3, 6, 12, 24, 48, 72 and 96 hours) and the number of new infectious progeny
virus was analyzed by titering each sample on BSC40 cells. The results indicated that
treatment with radiation, temazolomide, or both did not impact the viruses ability to
replicate in U188 cells (Fig 2B). Finally, to analyze the effect of SOC on the ability of MYXV
to spread from cell to cell, U188 cells were treated as described in the methods and
infected with various low MOIs (0.01 – 0.0001). At 24 hour intervals post infection,
pictures of individual GFP+ foci were taken and analyzed by measurement of GFP+ area
of foci images in Photoshop. No obvious morphological differences were observed in foci
formed following any of the treatment conditions (Fig 2C). A significant increase in foci
size, however, was observed 72 hours after infection between the untreated cells and the
cells treated with GBM SOC (Fig 2D, p < 0.05). Interestingly, this difference was not
observed in groups treated with either Temozolomide or radiation alone. To determine
whether this increase in viral spread also occurred in primary GBM patient samples, we
obtained GBM patient biopsies from patients in the neurosurgery department of MUSC.
Patient biopsies were harvested from three male patients who had not previously
undergone radio- or chemotherapy were excluded from the study. We then asked asked
how addition of SOC would impact MYXV infection of these samples. Samples were
harvested from patients on the day of their tumor biopsy and prepared for experimental
analysis as indicated below. Each sample was either mock treated or irradiated and then
infected with vGFP at an MOI of 5. Initiation and spread of infection was then assayed by
monitoring GFP expression every 24 hours after infection. While individual foci could not
be identified in primary slice cultures, the results clearly indicated increased levels of GFP
flourescence in GBM patient biopsies which were pretreated with radiation compared to
the nonirradiated samples 48 hours after infection (Fig 3).
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Figure 2:
SOC increases viral spread. (A) Cells were plated in replicates onto a 12 well plate. Percent
GFP+ cells were analyzed by flow cytometry 12 hours after infection with vGFP and
treatment as indicated in the protocol. Data represents summation of three independent
experiments (P < 0.05). (B) Cells were plated into replicates on 12 well plates. Number of
replication competent viral particles of MXYV were determined by titering after harvesting
from cells pretreated with the indicated treatment protocols in duplicate. Data represents
the summation of two independent experiments. (C) Cells were plated onto six well plates in
replicates. Images of GFP positive foci, infected with vGFP and treated as indicated, at 4x
magnification 72 hours after infection under fluorescent microscopy. (D) Mean foci area was
assessed at 24-hour intervals after infection with vGFP and treated as indicated for 72 hours.
There was a significant difference between cells treated with 1 Gy of radiation and
untreated cells (* = p < 0.011). Data representative of three independent experiments.
Statistical significance was determined using the Students T-Test.
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Figure 3:
SOC treated GBM patient Biopsies. Biopsies were collected from three patients with GBM.
Samples were prepared via the standard Stoppini Slice Culture as outlined. Samples were
then treated as indicated and infected with vGFP for 48 hours prior to imaging at a
magnification of 4x. Images taken via fluorescent microscopy.
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MYXV combined with GBM Standard of Care decreases Cell viability
We next set out to determine if the combination of viral treatment and SOC would
increase killing of GBM. In order to assess this, we assayed mitochondrial metabolism and
caspase-3 activity following treatment with MXYV in either the presence or absence of
SOC. Mitochondrial metabolism was analyzed by MTT assay and caspase-3 activity was
determined by colorimetric assay. To test for the possible species specific differences in
efficacy, we tested viability in three cell lines: U118 human glioma, T9 rat glioma and
GL261 mouse glioma. All three cell lines were infected at an MOI of 15 in either the
presence or absence of radiation, chemotherapeutic agent, or SOC. Absorbance of sample
was measured at 72 hours post treatment for both mitochondrial metabolism and
caspase-3 activity. While all monotherapies decreased cellular viability to some extent,
we observed that the combination therapy including MYXV, radiation and a
chemotherapeutic drug resulted in significantly higher decrease in cell viability compared
to any other condition (Fig 4A). These results were consistent across all three
chemotherapeutic drugs tested. Similarly, when using either Bevacizumab or Crizotinib as
the chemotherapeutic drug, we observed a significant increase in Caspase-3 activity when
cells were treated with the triple combination of MYXV, radiation, and drug (Fig 4B).
Interestingly, we observed a much lower increase in Caspase-3 activity with
Temozolomide than with either of the two other chemotherapeutic agents, though it was
still significantly different from SOC when combined with radiation and MYXV (Fig 4B).
Consistent with these results we observed both increased levels of cleaved Caspase-3 and
decreased phosphorylation of AKT in samples treated with MYXV and SOC (Fig 4C). We
again sought to confirm the previous results using primary GBM samples, which were
collected as previously described, to represent a more clinically relevant model. We
tested both mitochondrial metabolism, via MTT assay, and caspase-3 activity, via
colorimetric assay, in cells which had been extracted from the primary GBM patient
biopsies. Similar to what was seen in cell lines, the results demonstrated that the
combination of MYXV and SOC significantly reduced cellular viability of primary GBM cells
better than other treatment regimens (Fig 5A). This reduction in cellular viability was
again correlated with increased CASP3 activity and cleavage as well as decreased
phosphorylation of AKT (Fig 5B and 5C).
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Figure 4:
In vitro analysis of cell viability following treatment. (A) Cells were plated in replicates and
treated as indicated prior to infection with vGFP. Mitochondrial metabolism of U118 tumor
cells measured by MTT assay as percent of control at 72 hours post infection in. All
treatments resulted in significant decrease in viability compared to untreated cells (P <
0.001, individual values not shown). Combination therapy of Chemotherapeutic drug, MXYV
and radiation significantly reduced cell viability compared to all other treatment groups at 72
hours (*** < 0.001). Data is the summation of three independent experiments. (B) Cells were
plated in replicates and treated as indicated prior to infection with vGFP. Fold increase of
Caspase-3 activity compared to control was measured using a commercially available kit
described at 24-hour intervals post infection. Combination treatment of Chemotherapeutic
drug, MXYV and radiation significantly increased caspase-3 activity compared to any other
treatment groups at 72 hours (*** < 0.001, ** < 0.01). Data is the summation of three
independent experiments. (C) Western blot analysis of p-Akt, Caspase-3 and actin in GL261
mouse brain tumor cells, T9 Rat brain tumor cells and U118 human tumor cells. Samples
were treated with each chemotherapeutic agent either with or without radiation and MYXV.
Statistical significance was determined using the Students T-Test.
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Figure 5:
Ex vivo analysis of cell viability following treatment. (A) Patient biopsies were harvested and
cultured into duplicate 96 well plates and infected with vGFP and treated as indicated. Cell
viability of patient biopsies was measured by MTT assay as described at 24-hour intervals
post infection. Addition of all treatments resulted in a significant decrease in cell viability (P <
0.01, individual values not shown). Combination treatment of chemotherapeutic agent,
radiation and MYXV showed a significant decrease in cell viability compared to any other
treatment combination (*** < 0.001). Data is the summation of three independent
experiments. (B) Patient biopsies were harvested and cultured into duplicate 96 well plates
and infected with vGFP and treated as indicated. Caspase-3 activity of patient biopsies was
measured by the colorometric kit as described at 24-hour intervals post infection. Fold
increase of Caspase-3 activity was calculated as compared to control. Addition of all
treatments resulted in a significant increase in caspase-3 activity (P < 0.01, individual values
not shown). Combination treatment of chemotherapeutic agent, radiation and MYXV
showed a significant increase in caspase-3 activity compared to any other treatment
combination (***< 0.001). Data is the summation of three independent experiments. (C)
Western blot analysis of p-Akt, Caspase-3 and actin in three patient GBM biopsies. Samples
were treated with each chemotherapeutic agent either with or without radiation and MYXV.
Statistical significance was determined using the Students T-Test.
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MYXV Remains infectious at Room Temperature for an Extended Amount of Time
After showing that GBM SOC would synergize with the infection of MYXV we next
sought to find an effective way to deliver this combination to the tumor. Our approach
was to use the Alzet Osmotic pump which can deliver a continuous stream of
therapeutics. The osmotic pump consists of three parts, the tubing, a bladder and a
semipermeable salt wall. Over time, atmospheric water will pass through the salt wall
causing it to expand and adding pressure to the bladder. This increased pressure in turn
causes a constriction of the bladder and forces the solution out of the bladder and
through the tubing to the tumor. (Fig 6A). Previously, it has been shown that the use of
an osmotic pump is effective at delivering solutions of therapeutics both in vitro as well
as in vivo73-76. In order to ensure that this treatment would be sustainable for an extended
period of time we measured viral titer at various temperatures for a period of 96 hours.
Viral stocks were left at temperatures which corresponded to the control temperature (80°C and 4°C) as well as the temperatures expected if the pump is left over (23°C) or
under (37°C) the epidermis in either Temozolomide or sterile PBS. Samples were collected
at 0, 3, 6, 12, 24, 48, 72 and 96 hours following incubation at the indicated conditions.
Samples were then used to infect BSC40 cells and the titer was counted 48 hours after
infection (Fig 6B). Starting 48 hours after the onset of the experiment, there was both a
significant and constant drop in viral titer in the experimental temperatures compared to
both control temperatures. Furthermore at 96 hours, the sample incubated at 37°C had
a viral titer which was significantly lower then the samples incubated at the other
temperatures. Additionally the only significant difference seen by the addition of
Temozolomide was observed 24 hours after incubation at 37°C. It is important to note,
that while there was a significant decrease in viral titer, the virus which was recovered
from the samples was still infectious.
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Figure 6
MXYV stability. (A) Schematic of osmotic pump. Water molecules from the air
surrounding the pump infiltrate the bladder and cause an increase in pressure forcing
liquid in the bladder out and to the target. (B) Viral stocks were incubated at the
indicated temperatures in either Temozolomide or PBS and harvested over the span
of 94 hours. The harvested samples were then used for infection of BSC40 cells in
order to determine viral titer. Data representative of two independent experiments.
Statistical significance was determined using Students T-test.

Infectious MYXV is not recovered from the osmotic pump
Having shown that infectious MXYV was stable for up to 96 hours after incubation
at 37°C, we next sought to see how effective the osmotic pump would be for delivery of
the TMZ and MYXV combination. To measure the amount of virus being transported
through the pump we connected a collection tube containing 1mL PBS to the end of the
delivery tube and filled the pump with 100µL of stock virus. Samples were collected at
various timepoints (0, 3, 6, 9, 12, 24, 48 and 72 hours after pumping began) and used to
infect BSC40 cells in order to calculate viral titer transported over time (Fig 7A).
Interestingly, no virus was recovered at any time point in the collection tube. To test
whether the virus was moving through the pump mechanism we took additional samples
at each timepoint from these components and again recovered no virus. We next sought
to verify that liquid was being transported through the pump to the collection tube by
adding bromophenol blue to the viral stock. A standard curve was generated in order to
calculate the amount of bromophenol blue pumped over time based on absorbance of
the collection tube sample. The samples were then used to infect BSC40 cells to measure
viral titer transported over time. While we were able to pick up a steady rate of liquid
transport based on bromophenol blue, we again found no viral particles (Fig 7B).
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Figure 7:
Transport of viral particles through Osmotic pump. (A) Samples were collected in a 1.5mL
collection tube containing 1mL PBS over 72 hours. The sample was used to infect BSC40 cells
plated in 12 well plates for 48 hours to determine viral tier. (B) Bromophenol blue was added
to the osmotic pump to validate liquid transport. Absorbance was measured during
collection to calculate volume of liquid transported. Viral titer was determined as previously
described.
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Discussion
The poor outcomes of a GBM diagnosis have remained static over the years,
however, OV is to be considered a promising novel treatment option for GBM53. Current
oncolytic viruses, including: adenovirus, newcastle disease virus, herpes simplex virus,
poliovirus, measles virus, H1 parovirus, and reovirus have been tested against GBM
models and shown therapeutic efficacy77. While these viruses have shown oncolytic
potential, there is risk associated with their natural human pathogenicity. In light of this,
MYXV a non-human pathogenic virus which has previously been shown as an effective
oncolytic virus against multiple myeloma78, shows efficacy as a potential GBM
treatment33. While there is some literature which suggests that the combination of MYXV
and chemotherapeutics, such as rapamyacin69, may increase efficacy of treatment, little
work has been done to elucidate the interaction between MYXV and SOC for GBM. In this
study we were able to show that MYXV is a suitable oncolytic virus for GBM in vitro and
synergistically increases efficacy when combined with SOC.
In order to be effective, oncolytic viruses must initiate infection and successfully
replicate within tumor cells, resulting in cell death. Our results indicate that combining
MYXV with SOC does not alter initial infection or the ability of MYXV to replicate in GBM
cells. Importantly, we did observe that viral spread was increased upon MYXV infection
with both radiation and Temozolomide. Furthermore, a similar result was observed in
patient biopsies in terms of fluorescence both with and without radiation. The differences
between initial infection and spread are curious, and merit further inquiry. This could be
due to a number of factors, including alterations in cellular morphology, such as in cellular
junctions, which allows MYXV to spread between cells more effectively than under
normal conditions. Additionally, treatment of the cells with SOC could allow for increased
ability of the virus to egress from infected cells, either through changes in cellular
permeability or by some other mechanism and would explain the differences in the foci
forming assay but not in the single step growth curve. Additionally, as we see no
difference in the viruses ability to infect cells in the presence of GBM SOC indicating that
this effect has to do primarily with the viruses ability to exit the cell after infection.
We next decided to look the effect that our treatment protocol had on cell viability
by both an MTT assay and Caspase 3 colorimetric assay. The results of our MTT assay
show that the combination of SOC and MYXV greatly reduced cell viability compared to
either treatment alone. This increase correlated with similar increases in caspase-3
activation following SOC using all three chemotherapeutic drugs. Interestingly, while all
drugs showed an increase in Caspase-3 activity when combined with MYXV, a markedly
smaller increase was observed using temozolomide compared to either Bevacizumab or
Crizotinib. We hypothesize that this is a result of different mechanisms of action for each
chemotherapeutic drug. Temozolomide methylates the DNA of cells whereas
Bevacizumab targets the VEGF/VEGF-R interaction to prevent cell survival. Another
possibility is the half-life of Temozolomide, which is 1.8 hours in vitro. This could
potentially hinder treatment outcomes, especially over the course of experiments which
extend out several days. Additionally, these differences could explain why we do not
observe similar levels of caspase-3 activity when comparing the chemotherapeutics. As
these drugs have different targets, it is likely that they could activate cellular death by
17

different pathways. As Temozolomide shows less of a fold increase in caspase-3 activity,
it is likely that this drug induces cellular death via a pathway which is less dependent on
this protein. Future studies are needed to find the true cause of this difference.
In addition to our work in cell lines, we also tested the combination of MYXV and
SOC in primary GBM patient biopsies. We first saw that the addition of radiation to the
patient samples resulted in increased GFP expression in tumor slices, even in the absence
of chemotherapeutic drug. These results differ somewhat from our results with cultured
cells where the addition of both radiation and drug was needed to increase viral spread.
This could be due to the make-up of patient biopsies, as they contain more
heterogeneous cell populations than purified cultured cell lines. SOC may therefore affect
individual populations of cells differently and may explain the inconsistent results
between the biopsies and cultured cells. Further investigation into in vivo models is
needed in order to determine the potential cause of this difference and make the results
more clinically relevant to patient care.
Replication of the MTT and Caspase-3 assays in our ex vivo model showed similar
results as we observed in vitro. We did however, observe that the Caspase-3 assay
showed a larger fold change in activity from the ex vivo samples. This could be due to the
heterogenicity of the tumor cells from the patient biopsy versus that of the cultured cells,
which could be undergoing death by different mechanisms. These results could also be a
product of the harvesting process patient tumors where the stimuli of the patient specific
tumor microenvironment may affect how these cells react to different treatment than
the cultured U118 cell lines.
In addition to the determination of the synergistic relationship between GBM SOC
and MYXV, we sought to find an effective and non-invasive means to deliver this
treatment. For this we first showed that MYXV was stable for up to 96 hours at a
physiological relevant temperature of 37°C. Our stability findings were promising, given
that if the virus is able to remain in the pump for up to four days this would equate to a
patient replacing the pump at most twice per week. Additionally these results show that
the virus is sustainable in a solution of Temozolomide for at least a period of 96 hours.
This data suggests that we could supply patients with a single solution containing both
the viral stock and the chemotherapeutic without complete loss of the infectious virus.
The use of the osmotic pump is an attractive therapeutic tool because rather than
delivering a single high dosage of drug, the pump is able to deliver a constant low dosage
treatment to the tumor over a longer period of time. This would result in little to no
downtime in terms of treatment and possibly prove more efficacious overtime compared
to traditional means. This device may prove advantageous for viral infection as well.
Traditionally oncolytic viruses are administered as single high MOI injections over the
course of the treatment period. By supplying a low MOI injection over the span of several
days the cells in the tumor are constantly be infected and lysed through direct oncolytics.
This will, in theory greatly reduce tumor volume without allowing the tumor time to
produce new tumorigenic cells but also could signal a massive anti-viral and anti-tumor
response due to the constant release of both viral and tumor antigens. However, when
we tested our hypothesis that the pump will be able to deliver MYXV to the tumor we
found that, through several trials, no virus was recovered from the use of this system.
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Although we are not sure of the exact cause of this phenomena, there are several
possibilities. First is that the virus is binding to the bladder of the pump, preventing it from
being pushed through by water pressure alone. MYXV binds based on electrostatic
interactions and the pump used in this study is enclosed by a sodium wall which could
potentially interact with the virus and disrupt this electrostatic interaction. A second
possible explanation is that the virus is being inactivated either in the bladder or the
tubing on the way to the collection tube. Again, this could be due to the compositions of
either the tubing or the pump which due to electrostatic interactions results in the
passage of MYXV particles that are no longer able to infect cells. Further testing is needed
to elicit the mechanism by which this is occurring and possible resolutions which could
improve the osmotic pump in the delivery of this therapy modality. It is important to note
that a recent study has shown the poliovirus was able to be transported through a similar
osmotic pump. This finding suggests that the combination of virus and pump used may
be more complex then originally thought. Polio virus is a member of the Picornaviridae
family, which are characterized by an RNA genome surrounded by a protein capsid. MYXV,
however, is a member of the Poxviridae family of viruses, which are characterized by a
DNA genome surrounded by a viral envelope. This difference in outer coating of the virus
could explain why MYXV is non-infectious after incubation in the osmotic pump. An
additional cause of this could be in the inherent size of the virus. MYXV is comparably a
much larger virus than polio virus and as such may be a better viral model in terms of its
ability to be pushed through the pump components.
Taken together, this data suggests that MYXV combined with SOC can increase
efficacy of treatment for GBM by both increasing the apoptosis of tumor cells as well as
by enhancing the spread of viral infection. Whether this data suggests that such effects
would also deliver significant benefits in vivo, where the immunological impact of SOC
must be taken into account, remain to be determined. We hope that this data provides
the basis for subsequent studies looking at the combination of MYXV and SOC in a
biologically relevant model of GBM.
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Syncytia formation in oncolytic virotherapy
Introduction
While OV has shown promise in recent years as an anti-cancer therapy, it still
suffers from several fundamental issues which limit the treatment potential. The first is
the differential infection which occurs in the tumor microenvironment. As the tumor
microenvironment is a heterogeneous mixture of cell populations each with unique
mutations, individual tumor cells respond to OV treatment with varying levels of
susceptibility34, 79. This issue is particularly obvious in the ‘arming’ of the oncolytic
genomes to maximize phenotypes which are associated with improved treatment
efficacy80. Again, from this arming we see the differential infection of such treatment
modalities resulting in decreased treatment efficacy. Furthermore, this differential
infection leads to an inability of the virus to spread once it has infected tumor cells. By
inhibiting the spread of oncolytic viruses, the portions of the tumor which in unable to be
infected are ‘selected’ for and create an environment which is now fully resistant to OV.
A phenotype which has been shown previously to improve oncolytic potential is
that of virally induced syncytial formation. Syncytia are multinucleated cells created by
the fusion of neighboring cellular membranes (Fig 8). Syncytia appear naturally in certain
cell types, such as muscle cells, due to the abundance of gap junctions81-83. In other cell
types, however, syncytia often lead to either abnormal cell death or the spread of an
infectious pathogen, such as a virus84, 85. To date a number of naturally syncytia forming
viruses have been studied as potential oncolytic candidates86. These viruses spread
through both de novo infection and fusion of infected and uninfected cells which
increases their dissemination through the tumor and potentially improving overall
efficacy. Additionally, a variety of non-syncytia forming viruses have been genetically
engineered to artificially induce cell-cell fusion. The addition of the fusion protein is
attractive for a variety of reasons. First it the virus to spread both through traditional viral
infection, but also through the presence of the fusion protein. This can, in theory,
overcome the differential infection rate seen currently seen. Additionally, the use of
fusogenic viruses could overcome the ability of tumors to develop resistance to OV. As
many fusion proteins have several binding partners, many of which are common cellular
markers, it is less likely that the tumor would develop such a form of resistance. The
purpose of this section of the thesis is to review the current literature dealing with
fusogenic oncolytic viruses.
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Figure 8:
Schematic of syncytial formation. (A) Model of the interaction between an infected cell
which expresses the viral fusion protein. The protein will then bind to various receptors on
neighboring cell to induce syncytia formation. (B) Effect of syncytial formation as an
oncolytic treatment compared to a non-fusogenic virus.
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Natural Syncytia Viruses
Several viral families have evolved the ability to form syncytia between individual
infected cells and neighboring uninfected cells. During infection, this fusion is facilitated
by a viral fusion protein (often termed F) which mediates its function either with or
without the presence of additional viral proteins87, 88. A number of these naturally
occurring fusogenic viruses have been studied as oncolytic agents, including: newcastle
disease virus, sendai virus, respiratory syncytial virus, and measles. In addition to these
viruses other viral families can induce membrane fusion between viral particles and
cellular membranes. However, these viruses do not always cause subsequent syncytia
formation. For the purpose of this review we will limit our discussion to virus who
infection result in subsequent cell-cell fusion.
Newcastle Disease Virus
Newcastle disease virus (NDV) represents one of the first oncolytic viruses to show
clinical potential and has been studied for more than 60 years89-91. NDV differentiated
itself from other early oncolytic candidates both for its ability to infect a majority of
human cancers without the presence of a tumor specific receptor92 and its lack of
pathogenicity in humans93. This has allowed NDV to be used against a plethora of cancers
with relative success94-97. At least part of NDV’s efficacy is achieved through viral induction
of apoptosis98. Interestingly, while few studies have defined the mechanism through
which NDV induces it has been suggested that it is a cytotoxic effect of viral syncytial
formation99, 100. NDV achieves this through creation of a fusion complex which includes
both the viral F protein and the neuraminidase protein HN. The F protein is initially
transcribed as the inactive form (F0) and subsequently cleaved into the active
polypeptides F1 and F2 by cellular proteases of the host cell. It is this cleavage that allows
for the interaction of a mature F protein with HN and subsequently cell-cell fusion101.
While both F and HN are normally involved in the fusion of the virion with a host cell, they
can also induce direct cell-cell fusion when expressed on the surface of the host cell during
infection92. During NDV infection the relationship between F and HN plays a significant
role in determining the outcomes of syncytia formation. The presence of both proteins
results in efficient syncytia formation while, in the absence of HN, the F protein produces
an inefficient fusion phenotype characterized by an increase in cellular death102-104. It is
therefore possible that the specific role of syncytia during oncolytic NDV treatment might
be heavily influenced by the ratio of F to HN during a given infection.
This hypothesis is supported by the observation that NDV’s fusogenicity depends
on tumor cells resistance to apoptosis105. In tumors expressing BCL-xL, an anti-apoptotic
protein, both fusogenicity and cell lysis were enhanced upon NDV infection. While under
normal conditions syncytial formation activates apoptotic pathways resulting in rapid
cellular death, the upregulation of BCL-xL therefore promotes increased foci size over
time. It has previously bene reported that the upregulation of BCL-xL is able to confer
resistance to other treatment modalities under a similar mechanism106, 107. This is further
supported by the fact that once this protein is knocked out of cells, the ability of the virus
to form syncytia is extremely hindered, presumably due to the inability of tumor cells to
prevent apoptosis from occurring once the syncytia begin to form. By hijacking the tumors
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own anti-apoptotic pathways, fusogenic viruses could form larger syncytia, thereby
releasing vast amounts of neoantigens which result in greater anti-tumor responses
downstream. Critically, this spread is still limited to malignant cells since normal cells are
somehow excluded from this selective syncytium formation.
Prior to this study, two other studies were done to assess the efficacy of a mutated
form of the NDV virus. The mutated virus was found to be hyperfusogenic due to a
multibasic cleavage component of the F0 protein108, 109. Together, these studies show the
correlation between fusogenicity and efficacy in oncolytic treatment both in
hepatocarcinoma cell lines. In both cases this increase in efficacy is related to the loss of
need for the HN attachment protein. The independence from HN aids in NDV because it
allows the fusion protein to bind with less specificity than it would with HN, which is
specific for particular receptors. This allows for more inclusion of the heterogeneous
tumor population and ultimately a more robust anti-tumor response. Surprisingly, both
papers go on to show that this increased fusion potential does not increase cytoxicity to
healthy cells. Additionally, it was found that the hyperfusogenic strand still possesses the
ability to selectively target cancer cells. These finding are significant in that they provide
evidence that the fusion protein can be modified yet maintain the viruses oncotropic
nature.
Sendai Virus
Sendai Virus (SV) is a member of the same viral family as NDV and the two viruses
likely possess similar oncolytic characteristics110. Compared to NDV, however, the
oncolytic potential of SV is less well-studied, although it also appears to have potential
against a wide range of cancers111, 112. Like NDV, SV forms syncytia upon infection which
results in the induction of apoptotic cell death111, 113. Unlike NDV, however, while SV’s
fusion complex does include HN, fusion is not strictly dependent on expression of the
second protein114. SV’s fusion is associated with the initial translation of an inactive F0
protein and the formation of sulfide bridge linked subunits (F1 and F2) and subsequent
fusion independent of additional accessory proteins115.
Importantly, there have been recent studies which directly discuss the role that
syncytia formation plays in SV-based therapy112, 113, 116. A publication by Hasegawa et al.
shows an example of the oncolytic potential of SV. The study demonstrates that the use
of a fusogenic SV strain can increase both the spread and cytotoxicity from viral infection
by as much as four times that of a non-fusogenic counterpart across a range of
glioblastoma (GB) tumor lines. These results are then translated to an in vivo model in
which tumor volume was reduced significantly compared to both mock and a nonfusogenic virus as well as doubling survival when comparing the same groups112. This
study is of particular interest due to the unique physiology of GB tumors. Therapies
focused on treatment for GB are especially important because standard of care for GB is
generally inefficient at curing the entire tumor, particularly in regards to treatment of
brain tumor initiating cells (BTICs). It has previously been shown that OV is effective at
treating BTICs69, 71 but is less efficient at treating the differentiated tumor cells. Thus, a
form of OV which is able to elicit complete tumor regression is a highly attractive option.
Unfortunately, this study does not address one of the largest concerns of using a
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fusogenic virus, particularly in the context of GB tumors, in terms of toxicity with the
normal cells surrounding the tumor. Again, this is of particular interest for GB tumors as
they represent a more diffuse tumor than many other tumor models. As a GB tumor
grows, the afflicted cells began to infiltrate the surrounding normal tissue resulting in an
extremely heterozygous cell population that is difficult to treat by surgical or radiological
targeting117. It is for this reason that a viral treatment that is effective against both BTICs
as well as differentiated tumor cells is such an attractive option if the virus remains highly
tumor specific with the addition of the fusion protein. Future studies will need to elicit if
this is indeed the case before moving forward to clinical trials.
A possible explanation to why fusogenic viruses show increased efficacy was
offered in a study from 2008. In this study, the research team found the presence of the
F protein resulted in an upregulation of IL-6 118. The importance of this finding is that IL-6
is associated with the inhibition of T-regulatory (Treg) cells119. Tregs function to inhibit
cytotoxic T-cells as a protection against autoimmunity. However, during immunotherapy
Tregs can act as inhibitors of the adaptive immune response and exhaust cytotoxic T-cells,
subsequently lowering the efficacy of treatment. IL-6 has been seen as a means to prevent
this process from occurring by inhibiting the differentiation of Tregs, ultimately reducing
their abundance. The fact that the F protein of SV can trigger IL-6 upregulation could
explain part of the reason for an increased efficacy with fusogenic viruses. While a more
potent anti-tumor response will be mounted with the inclusion of more cells into the
syncytia, the ability of Tregs to turn off this cytotoxic T-cell response will be diminished
and provide an overall increase in efficacy. This finding raises the question as to whether
or not this is an isolated phenomenon which only occurs with the F protein of SV or if all
fusion proteins produce similar effects.
Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) was originally identified as on oncolytic virus due
to the degree of sensitivity that it exhibits towards interferon (IFN). As cancer cells have
frequently lost the ability to respond to IFN, this allows for highly oncotropic infections
using RSV120. In the case of RSV the fusion protein similar to that of NDV and SV in that it
is transcribed in an inactive form which then undergoes additional processing to the
active form. The F0 protein is cleaved by furin to produce the active complex consisting of
two subunits, F1 a C-terminal membrane anchored subunit, and F2, the N-terminal
subunit. RSV also encodes an additional glycoprotein (G) which aids in the fusion
capability of the virus, however, this protein is not strictly required to induce infection or
fusion121-128. The ability of RSV to initiate fusion with neighboring cells independent of coexpressed attachment proteins could potentially making this virus a more versatile
inducer of syncytia formation. This would be due to the ability which the F protein has to
bind and initiate fusion, in the absence of its accessory protein which serves simply to
accelerate the process of fusion but is not an essential component of the fusion
mechanism. A previous study has shown that a RSV strain lacking these proteins remains
a functional virus126. Unfortunately, despite this theoretical versatility, the direct role that
syncytia formation plays in RSV-based oncolytics remains poorly defined
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A 2015 paper by Choi et al., demonstrates that infection with RSV resulted in a
reduction in the growth of some, but not all, hepatocellular carcinoma cell lines and that
syncytia formation was specifically present in the cell lines which showed a decrease in
cellular growth due to the increased cell death as a result of the infection. Additionally,
this paper suggests that this lack of cellular growth was in part due to the ability of RSV
to cause cell cycle arrest, preventing cell division129. A second study obtained similar
results in a variety of skin carcinoma cell lines, however, this work also showed that the
infection with RSV resulted in increased apoptotic cell death which correlated with
syncytia formation130. Unfortunately, neither paper directly examines if there is a
mechanistic relationship between syncytia formation and the inhibition of cancer cell
growth. RSV dependent syncytial formation, however has been shown to result in
activation of apoptosis via p53, which could explain the apparent correlation131, 132. In the
context of cancer however, while the ability to kill cells is an important, it is interesting to
look at the ability to arrest the cell cycle as being equally important. This is especially
important with regards to tumors which are often associated with a rapid cell cycle. With
fusogenic virus, the ability to arrest the cell cycle seems highly likely because of the
disruption of cellular components that occurs from syncytial formation. Given that the
nuclei of fused cells localize upon formation of the syncytia, it is possible that the cells are
then unable to correctly initiate the cell cycle and division process and this in part leads
to the rapid cell death associated with the formation of syncytia, due to the inability of
the now giant cell to maintain the nuclear stability associated with having several nuclei.
Future studies should look into this notion and attempt to elicit the role that syncytia
formation has on cell cycle mechanics.
Measles Virus
The oncolytic potential of genetically modified Measles virus (MV) has been
known since the 1970s133, 134 . Since then, the virus has been used against a wide range of
cancers from many different tissue types, including: lymphoma, leukemia, gliomas and
osteosarcoma135-138. MV induces cell to cell fusion via expression of the MV-F protein and
its interaction with the hemagglutinin protein H139. Similarly to the NDV and SV F proteins,
MV-F is initially translated as an inactive form. This precursor form cannot interact with
the H protein to create the fusion complex unless MV-F is cleaved by the appropriate
proteases during the process of vesicular trafficking of the translated protein in order to
form the active variant140-142.
A 2015 paper shows the positive effect that MV has on atypical teratoid rhabdoid
143
tumor . While this is a rare cancer subset, this work is interesting because it shows that
MV is able to greatly reduce tumor burden in mice, primarily due of the formation of
syncytia. This paper offers two key findings which are key to syncytia formation as an
oncolytic tool. First is the finding that of a low MOI which is sufficient to drastically reduce
tumor cell viability at as early as 72 hours after infection. Secondly is the finding that the
use of fusogenic MV was able to prolong survival both in a localized as well as metastatic
tumor model. Together these results show that the virus is effective at rapid clearance of
the tumor, even at low MOI, but as well as mounting a potent anti-tumor immune
response after this eradication of the localized tumor. This group has previously shown
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that similar results were seen in the context of medulloblastoma144. The use of a single
viral vector in the context of several different cancer models showing similar efficacy is a
promising finding, as it shows that the virus is able to overcome the specify which is often
seen in OV treatments. These results expand on an earlier study which showed how MV
could increase the survival period of tumor burdened mice compared to that of a heat
inactive virus control138. In this work, survival was associated with increases in cytotoxicity
correlated with syncytial formation and activation of the TLR-7/9 anti-viral signaling
pathways.
While both of the previous papers discuss how fusogenic MV can be used against
fully differentiated tumor cell lines, tumor initiating cells (TICs) pose a much greater
challenge in terms of therapeutic outcomes and techniques145-147. These cells are often
resistant to most conventional treatments and are a primary cause of relapse for cancer
patients148-150. It is critical to note then, that MV-induced syncytia can apparently include
gliomal TICs based on the inclusion of the CD133 marker. This inclusion results in direct
cytopathic effects to the TICs and can significantly prolong survival137. This work
demonstrates an important characteristic of syncytial forming viruses in that they can
often form syncytia with cells near to them regardless of these cells susceptibility to direct
viral infection. This allows syncytia forming oncolytic viruses to spread to both
differentiated tumor cells and TIC’s offering a much greater therapeutic potential then
many conventional therapeutic options. This finding, however, also raises questions as to
the potential toxicity of fusogenic viral constructs. Future studies should therefore look
into the ability of syncytia to fuse infected cells with both cancer cells as well as healthy
cells if the F protein is exposed to the proper conditions. Due to the ample number of
binding partners which fusion proteins often have, it is plausible that the cancer specific
nature of oncolytic infection could be broken resulting in lysis of malignant and healthy
tissue. If this proves true, novel ways in which to restrict the binding of F proteins solely
to tumor cells must be identified.
Engineered Syncytia Viruses
With recent advances in molecular cloning and improved understanding of viral
genomes, it is now possible to increase the oncolytic potential of many viruses through
the addition or removal of specific genes. The goal of these changes is to increase or
decrease phenotypes associated with strong oncolytic potential including: various aspects
of the immune response (NK cell inhibition, CD8+ T cell activation, checkpoint blockade
inhibition, etc.), lysis of infected cells, or spread within the tumor. One approach scientists
have begun studying is to insert the fusogenic proteins of naturally occurring syncytia
viruses into the proven backbones of non-fusogenic oncolytic viruses in order to enhance
the spread of these viruses through the tumor. This combination allows for oncolytic
viruses to benefit from the increased spread caused by syncytial formation, while
maintaining the inherent oncolytic properties of their non-fusogenic backbones. In
addition to increased spread, inducing syncytia formation can also bypass the receptor
dependence which limites the therapeutic potential of some viruses. A variety of common
vectors and fusion proteins have been used during these studies.
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Recombinant Vesicular Stomatitis Virus
Vesicular stomatitis virus (VSV) is a cattle pathogen which is largely nonpathogenic in humans. Similar to RSV, VSV has been shown to preferentially replicate in
tumor cells due to its restriction by functional interferon responses151, 152. In addition to
its natural oncolytic potential, VSV is also frequently used to create recombinant viruses
since the virus offers significant freedom to add therapeutic genes to the genome without
compromising other aspects of the viral biology153.
One example of such a recombinant virus is that of the VSV-H viral construct which
encodes the MV-F protein into the VSV genome as well as the H attachment protein154.
This virus maintains the tumor-specific binding seen in VSV in the prescence of IFNbeta155, while also implementing the CD46 specific fusion mechanics of MV. However, the
new recombinant virus possesses greater all-around oncolytic capacity than either wild
type parental virus. This increased capacity is partially due to the removal of the
endogenous G protein of the VSV vector. With the removal of this protein, VSV induced
membrane fusion is no longer limited by the pH dependence of its G protein, giving the
recombinant virus a more general fusion ability than the wildtype vector156-158. This
increased ability to produce syncytia results in the generation of significantly larger
plaques than those seen with wild-type MV as well as infection which is independent of
CD46 receptor density159. This CD46 independent fusion offers a significant therapeutic
advantage since the specificity of binding is no longer limited to CD46 expressing tumor
cells. Another recombinant VSV/MV-F recombinant virus also displayed cytotoxic effects
against TIC’s, again independent of CD46-based viral entry, suggesting a second possible
mechanism through which improved oncolytic potential might be obtained160.
In addition to insertion of MV-F, insertion of NDV-F into VSV was also shown to
improve oncolytic potential161. In wildtype NDV, fusion is induced by a two-step binding
process. First, hemagglutinin-neuramidinase mediates the attachment of the virus to the
target cell through the sialic acid rich surface receptors of the target cell. This interaction
is subsequently followed by the induction of fusion between the virus and target cell by
the NDV-F protein. It is important to note however, that the recombinant NDV-F protein
often possess a unique mutation that allows for the induction of fusion independent of
the HN glycoprotein161. In this instance, treatment with a VSV containing NDV-F resulted
in prolonged survival in both metastatic liver and lung models. This enhanced efficacy
correlated with increased viral infection when compared to a non-fusogenic control virus.
Importantly this study also demonstrates the specificity which comes with syncytia
formation. The study explicitly looks at the surrounding tissue in order to determine the
toxicity of introducing a fusogenic viral construct in an in vivo mode, concluding that the
fusogenic virus does not form syncytia with the surrounding normal tissue. A later study
using this same recombinant virus also showed benefits in metastatic colorectal cancer
models, as well as similar lack of toxicity to the neighboring organs162.
The exact mechanism by which this exclusion of syncytial formation occurs
however is not described in either study, but this question offers an intriguing path of
investigation for future studies. If this mechanism proves to be due to the normal cells
ability to respond to interferon then fusogenic viral treatment would be assumed to be a
safe form of treatment regardless of tumor subtype as it would continually offer tumor
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specificity. If, however, the mechanism proves to be based off the surface receptors which
interacts with the F protein, this will pose a greater challenge for fusogenic virus as
oncolytic agents due to the fact that each tumor subpopulation and the surrounding
normal tissue, would have to be prescreened for the possible binding partners of each
individual F protein being used.
Recombinant Herpes Simplex Virus
Herpes simplex virus (HSV) is a normally non-fusogenic human pathogen that has
been used as an oncolytic virus in both its natural and engineered states163-165. While HSV
can acutely form syncytia in its wildtype form the majority of HSV oncolytic trials,
including the ones which led to the recent FDA approval of Iymlygic166, have been done
using recombinant HSV vectors armed with non-fusogenic inserted transgenes, proving
that HSV is capable of harboring additional genes in order to enhance its oncolytic
capacity. Several studies have since begun to look at the possibility of adding fusogenic
proteins into the HSV genome. The addition of such proteins offers a two-fold benefit.
First, it allows the virus to adopt new forms of oncolytic prowess that otherwise were not
capable of having prior to this insertion. Secondly, with new means of oncolytic potential
the virus is able to infect a larger subset of tumor cells and provide more complete
oncolytic activity.
One such fusogenic virus is the recombinant HSV-GALV fusion virus167-169 which
combines the oncolytic HSV backbone with the fusogenic Gibbon Ape Leukemia virus
fusion protein. While GALV has poor oncolytic potential alone, the virus is hyperfusogenic
and insertion of its F protein into other viral vectors has previously been reported to
generate a fusogenic construct with significantly increased oncolytic potential170. Studies
using this virus have shown that addition of the GALV-F protein increases the death of
infected tumor cells by up to 54%. Critically these studies also observed substantial death
of uninfected tumor cells across several cell lines: including colorectal adenocarcinoma,
glioblastoma astrocytoma and lung epidermoid carcinoma both in vivo and in vitro. This
work clearly highlights the importance of cell death via the bystander effect which is
defined as the programmed cell death of nearby cells due to the release of cytokines from
infected cells171-173. While death of infected cells is important for direct oncolytics, the
death of cells that were not part of the initial infection is a major focus of oncolytic
immunotherapy174, 175 and provides the possibility of a wider and more efficient antitumor immune response that has much more therapeutic potential then direct oncolytics
can initiate by itself.
In light of such positive findings in a single intertumoral model, research naturally
advanced towards looking at the use of fusogenic HSV against metastatic disease. In this
double fusogenic construct, a HSV vector which had previously been pre-isolated for the
ability to form syncytia, known as Synchro-2D176, was combined with the hyperfusogenic
F glycoprotein of GALV177. Early studies showed the efficacy of a double fusogenic HSV
recombinant virus, which encodes two distinct fusogenic proteins, against both
metastatic ovarian cancer and breast cancer. The purpose of a recombinant virus
encoding two separate fusion proteins was to combat the potential development of
fusion resistance. Additionally, with the increased fusion and subsequent cell death the
28

virus is released into the tumor microenvironment at far greater levels (over 90% of the
viral progeny) and results in much higher rates of spread. This could possibly explain the
significant results seen in metastatic models, due to the virus now infecting cells over
farther distances after this rupturing of the initially infected cells. In addition, the group
led by Zhang found that, against metastatic ovarian cancer models, the double fusion viral
construct resulted in both increased death as well as complete curing of most of the
treated mice when compared to the untreated control and non-fusion viral construct
groups178. This group however neglected to compare the results of a double fusogenic
HSV construct with one that had a single fusion protein. Without this comparison it is
difficult to say how much added effect the addition of the second fusion protein has on
the outcome of this model or if one such protein will yield the same results. Additionally,
the study does not look into the immunological effects of this construct in the context of
metastatic tumors
While these previous studies lay the foundation for the idea that syncytial
formation induces a stronger anti-tumor immunological response than that of the nonfusogenic viruses, they do little to understand the reasoning and mechanics behind this
concept. Other studies also go on to suggest that an increase in anti-tumor lymphocytes
provides an immune response against both localized and metastatic disease120, 179, 180.
Similar results were shown when changing the fusogenic protein to GALV, which implies
that strong anti-tumor immunological effects are not specific to the fusion protein added
to the virus vector, and that the formation of syncytia activates the same immunological
pathway regardless. In such studies tumor reduction was significantly greater than that
of non-fusogenic HSV which was still able to show significant oncolytic capacity164 both
locally as well as on tumors that were treated with the virus after metastasis had
occurred. The results of the study showed complete reduction in tumor burden in several
mice given the fusogenic treatment. The study implies that the reason for such a robust,
anti-tumor immune response is primarily the benefits of the added bystander effect. The
bystander effect refers to how uninfected cells are killed as a result of the viral
infection173. The increased activation of the bystander effect leads to a larger portion of
the tumor being eliminated simply through the initial infection. With more cells being
killed, there is now more antigens from the tumor able to be presented to T cells by
antigen presenting cells. This results in a larger immune response, particularly against
subpopulations of the tumor that were previously uninfectable by virus and thus a more
complete tumor eradication. However, it is important to note that these results may have
arisen from the combination of several factors rather than the formation of syncytia alone
as several papers report this phenomenon with oncolytic viruses which also possess
expression of cytokines. While several studies point to syncytial formation inducing the
bystander effect it is still poorly understood and should be the focus of future studies to
show what role it serves when incorporated into fusogenic OV181, 182.
Fusion-Associated Small Transmembrane Protein Recombinant Viruses
Fusion-associated small transmembrane (FAST) proteins are a class of membrane
proteins which promote cell-cell fusion and syncytia formation183. FAST proteins are
forms of recombinant F proteins from various fusogenic viruses which allow for any virus
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to then possess fusogenic capabilities. Since these proteins ultimately induce syncytia,
however, the results of their insertion into recombinant viruses are hypothesized to be at
least comparable to naturally occurring fusogenic viruses.
A 2017 study shows just how efficient this protein class can be when combined
into a VSV recombinant virus. The results of this paper demonstrate that viruses which
encode FAST proteins are able to induce syncytial growth in vitro. The study then goes on
to demonstrate that treatment with the recombinant virus leads to a reduction in the
growth of established tumors in vivo. Additionally, VSV-fast treatment also reduced the
size and number of metastatic lesions184. This finding was not seen with non-fusogenic
control viruses suggesting that the ability of the recombinant virus to form syncytia may
have resulted in an increase in the adaptive immune response. This immunological
activation correlated to an increase in activated, indicated as CD69 positive, CD8 as well
as CD4 positive T cells. This finding was particularly interesting because of the nature of
the tumor model being used. By showing that the fusogenic virus could slow progressive
in such an aggressive model, this study provides clues that the response rate for the use
of a syncytial virus is much quicker than that of the non-fusogenic counterpart. This seems
to address the largest drawback to OV as a standard of care, the inability of the virus to
spread rapidly enough throughout the tumor and provide a circumvention to make this
form of therapy an excepted form of care for both localized and metastatic diseases.
Alternatively, earlier studies showed that FAST proteins themselves also possess a strong
cytotoxic effect and their expression can lead to levels of cell death comparable to
naturally syncytia forming viruses169, 185-188. These studies verify am important point about
fusogenic proteins. This fact is that fusion proteins are not specific to the viral vector from
which they were isolated and thus can be inserted into the viral genome of any virus. This
allows for the modification of any viral vector and opens the door to the generation of
designer viral constructs which possess several novel transgenes such as fusion proteins
to increase efficacy while still maintaining the unique efficacy of each individual gene.
While FAST protein recombinant viruses are not as abundant in the literature as
other recombinant viral strains, the notion and principle of adding such genes to create
new recombinant viruses is a promising idea. Studies into how these proteins may
increase immune response both in the localized tumor as well as in secondary metastatic
lesions will allow for the most powerful combination proteins and viral vectors to mediate
the most efficient immune responses. Additionally, if the exact mechanism by which FAST
proteins activate the anti-tumor immune response future studies can focus on creating
newly armed fusogenic constructs which enhance this pathway further.
Conclusion
Syncytia are defined as the fusion of cells into a single multinucleated cell body.
The intention of syncytia formation, from an evolutionary perspective, is to increase the
spread of a virus through fusion of both infected and uninfected cells. Thus, this process
represents a novel solution to one of the biggest challenges facing OV. By combining
fusogenic viruses and OV, scientists have proven that syncytia both can and will kill tumor
cells effectively regardless of tumor type. While these results show the promise of
syncytial forming viruses, there is still the question as to how syncytial formation causes
durable responses following therapy. It is believed that the formation of antigen rich
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vesicles known as syncytiosomes provide an increased immune response which is
responsible for both efficacy against metastatic disease as well as long-term durable
responses120, 186. Syncytiosomes are exosome-like vesicle associated with a particular
death pathway dealing with syncytia formation and the subsequent release of vast
amounts of antigen from the fused cells. It has been proposed that the fusion of cells into
a syncytial body results in an increased release of these exosomes, which are then taken
up by antigen presenting cells resulting in increased cross-presentation of tumorassociated antigens on major histocompatibility complex molecules120. Several studies
have shown that syncytial formation can have long lasting immunological effects on the
tumor response and may aid in explaining why syncytial forming viruses show such
promising oncolytic effects121, 189, 190. Work is still needed, however, to elucidate the exact
mechanism by which syncytia induce an adaptive immune response.
A key feature of successful oncolytic viruses is the ability to selectively infect
tumor cells over normal cells. The syncytia produced by fusogenic viruses are products of
the viral infection, however, how the oncotropic specificity of the infection is maintained
during syncytia formation is unclear. One recent study suggests that syncytia
preferentially form in infected tumor cells rather than normal cells when forming a
syncytial body186. Several other studies discuss the role that syncytial formation plays in
OV toxicity as being minimal, suggesting that syncytia are mainly including tumor cells
over normal cells. However, future studies will need to focus on this question in order to
make syncytia forming viruses a mainstream component of OV.
With such a vast selection of viruses for scientists to use, it seems as if oncolytics
is poised to make great leaps in cancer therapy in the years to come. Syncytia forming
viruses, both naturally occurring and engineered, offer a new tactic to overcome one of
the greatest problems in OV, viral spread within the tumor microenvironment. The work
which has been done to date is promising and offers many possibilities for the future of
oncolytics, however, additional studies are still needed in order to understand and fully
utilize the concept of syncytia formation during OV. For instance, how fusion proteins
from different viruses compare to one another in terms of oncolytic potential. With slight
differences in fusion proteins between viruses, it seems likely that these would result in
some difference when used and oncolytic viruses. Syncytial forming viruses are gradually
gaining ground as a powerful tool for OV, and with many questions still to be answered
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Fusogenic Myxoma virus as a Novel form of Oncolytic Virotherapy
Introduction
As previously mentioned, MYXV is an attractive oncolytic both for the non-human
pathogenicity of the virus and the ease of introducing novel transgenes by genetic
modification33. As with many oncolytic viruses, MYXV suffers from a limited spread in vivo
which can hinder the efficacy of treatment. However, it has not previously been shown
how the addition of a fusion protein would affect the efficacy of MYXV. Additionally, there
has yet to be a study in which viral fusion proteins of different viruses have been tested
concurrently. The third and fourth specific aims of this thesis look to address the efficacy
of fusogenic MYXV constructs. We first sought to test the hypothesis that the addition of
a fusion protein would increase spread in vitro without hindering viral properties. While
it is true that the MYXV genome can be easily altered, it is important to ensure integrity
of the inherent viral characteristics when disrupting the genome. In addition to ensuring
that the viral constructs function as normal, we hypothesized that the ability for MYXV to
form syncytia would result in greater spread across multiple cell lines. Additionally, this
increase in spread would result in an increase in cellular death because as the syncytia
becomes larger the integrity of the multi-nucleated cell suffers. We next sought to test
the hypothesis that these in vitro results would translate to better efficacy in in vivo.
Syncytial formation is correlated to higher bystander effect in the tumor
microenvironment. As the syncytia grows and eventually lyses, nearby cells will also
undergo cellular lysis as a result of the release of apoptotic vesicles 173. We hypothesized
that this bystander effect would result in the abundant release of tumor antigens and a
more robust anti-tumor T-cell response.
Results
Validation of fusogenic construct generation
To test whether the addition of novel fusogenic transgenes would increase
efficacy of MYXV, we first had to generate and validate the new viral constructs in vitro.
To generate the constructs, we first started with the pBluescript M135/GFP/M136 vector.
Into this vector we inserted four unique viral F proteins (NDV F, RSV F, Nipha virus F and
BPV F). Each fusogenic protein was mutated from the wild type to be hyperfusogenic as
well to induce fusion independent of a secondary protein. The F proteins were also
mutated so that they would be expressed on the surface of the cell. The F proteins were
placed under a synthetic early/late promotor to induce fusion shortly after viral infection.
Finally, the F proteins were myc tagged on the C-terminal for verification.
To validate that we had generated fusogenic constructs, BSC40 cells were plated
into 6 well plates and infected at an MOI of 10. Images were taken and samples harvested
24 hours after infection and tested for the presence of the myc tag by western blot.
Western blot analysis revealed the presence of the myc tagged fusion protein in vGFPNDV, vGFP-NFP and vGFP-BPV (Fig 9B), with vGFP-RSV being the only construct which
lacked this signal. We also observed a decrease in signal of GFP in the vGFP-RSV construct
which was not present in the other fusion constructs. Interestingly, we observed a clear
syncytial phenotype in two of the four constructs (vGFP-NDV and vGFP-RSV) which was
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not observed in the other two (Fig 9C). We next sought to validate these constructs using
the definition of syncytia: a multi-nucleated cellular body. BSC40 cells were plated on
15mm glass coverslips in 12 well plates and infected at an MOI of 0.001 for 24 hours. Cells
were then stained with Hoerscht stain and mounted using Vectashield with phalloidin
per manufacturers recommendations (Fig 10). Slides were then imaged using an Olympus
FV10i laser scanning confocal microscope. In both the vGFP-NDV and vGFP-RSV constructs
there was a clear change seen in the cytoskeleton which corresponded to GFP+ areas.
Additionally, the nuclei of several cells were encapsulated in the syncytia. The vGFP-NFP
construct exhibits a less severe syncytial phenotype characterized by the multinucleated
infected cells and larger infected cell, however it appears that the entire infection does
not fuse within itself as observed in the previous two constructs. Additionally, it appears
that the vGFP-BPV construct does not form syncytia. This is evident by the similarity in
appearance to that of vGFP.
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Figure 9:
Verification of construct (A) Cloning strategy for viral constructs. (B) Western blot verification
for presence of myc tagged fusion protein. BSC40 cells, plated into six well plates were
infected for 24 hours at an MOI of 10. Samples were then stained for actin, gfp and the myc
tag. (C) Validation of construct through syncytial formation. BSC40 cells plated into six well
plated were infected with an MOI of 10. Images were compared to the non-fusogenic vGFP
control construct.
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Figure 10:
Immune Flourescent characterization of syncytial formation. BSC40 cells were plated on
15mm coverslips into 12 well plated and infected with and MOI of 0.001. Coverslips were
stained with Horescht stain and mounted onto glass slides using anti-phalloidin
Vectashiled. GFP+ area is outlines in white in the Actin/Dapi overlay, to visualize infected
region of infection. Slides were imaged using the Olympus FV10i laser scanning confocal
microscope. Images were taken at 40x.

Syncytial formation increases MYXV spread in vitro
Having validated that we generated the fusogenic constructs of MYXV, we next
sought to test the hypothesis that this phenotype would increase spread in vitro. BSC40
cells were plated into six well plates and infected at various low MOIs (0.01-0.0001). At
24-hour intervals post-infection, pictures of individual GFP+ foci were taken and analyzed
in ImageJ. GFP+ area, was increased 72 hours after infection in both the vGFP-NDV and
vGFP-RSV compared to vGFP (Fig 11A, P < 0.01), however this increase was not observed
in the vGFP-NFP and vGFP-BPV constructs. This experiment was then repeated in a A9F1
cell line, to examine the syncytial formation in a relevant tumor model. Again, we
observed a significant spread increase with both the vGFP-NDV and vGFP-RSV constructs
compared to vGFP but not with the vGFP-NFP or vGFP-BPV constructs (Fig 11B, P < 0.05).
We next sought to determine if the addition of these novel transgenes to the MYXV
genome would negatively affect the ability of the virus to generate infectious progeny
after infection. To test this question, BSC40 cells were infected with each construct at an
MOI of 10. The samples were harvested at various timepoints (3, 6, 12, 24, 24, and 48
hours) after infection and used to infect BSC40 cells. Titer was determined by number of
GFP+ foci at 48 hours post infection. We found no significant difference in number of foci
between the constructs at any given timepoint (Fig 11C, P > 0.05). Having shown both an
increase in spread as well as no impact on viral titer we next looked at the potential
efficacy of these new constructs. In order to test the cytotoxicity of these newly generated
MYXV constructs we infected various cell lines (BSC40, A9F1 and GL261) plated in 96 well
plates at an MOI of 10. Measurements were taken 48 hours after infection (Fig 11D). We
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observed a significant decrease in cellular viability in both the vGFP-NDV and vGFP-RSV
constructs compared to vGFP in the BSC40 cell line (P < 0.001). A significant decrease was
also seen in the vGFP-NFP construct, but this was less significant than the previous two
constructs. In the A9F1 model, while there were decreases in cellular viability in in the
vGFP-NDV and vGFP-RSV constructs compared to vGFP these decreases were not
significant. Interestingly, we observed an increase in cell viability in both the vGFP-NFP
and vGFP-BPV thought it was not significant. Finally, we a significant decrease in cellular
viability in all four constructs when compared to vGFP in the GL261 cell line. We next
sought to test the ability of fusogenic MYXV constructs to spread in an interferon (INF)
responsive cell line to test potential toxicity of the constructs. MEFs were plated onto six
well plates and either pretreated with INF-β or left untreated 24 hours prior to infection.
MEFs were then infected at various MOIs (0.01-0.0001) and imaged at 24 hour intervals
for 72 hours. In the presence of INF-β, we saw no viral infection with any construct (Fig
12A). Interestingly in the untreated cells, while we observed viral infection in all
constructs we did not see an increase in spread in any of the fusogenic constructs
compared to vGFP (Fig 12B). From images taken of GFP+ foci, we observed that infection
of MEFs with the fusogenic MYXV constructs did not result in syncytial formation as seen
in other cell lines (Fig 12C).
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Figure 11.
In vitro characterization of fusogenic MYXV constructs. (A) Mean foci area was measured at
24-hour intervals after infection with each viral construct for 72 hours in BSC40 cells. There
was a significant difference between the vGFP-NDV and vGFP-RSV constructs compared to
vGFP (* = P<0.01). Data are representative of three independent experiments (B) Mean foci
area was measured at 24-hour intervals after infection with each viral construct for 72 hours
in A9F1 cells. Again, there was a significant increase in spread for both the vGFP-NDV and
vGFP-RSV constructs compared to vGFP (* = P<0.01) but not in the other two, which saw a
decrease in spread compared to vGFP. Data are representative of three independent
experiments (C) Single step growth curve of viral constructs infected onto BSC40 cells at an
MOI of 10. Cells were harvested over the span of 48 hours. No significant change in viral titer
was seen in any construct. Data are representative of two independent experiments (D) Cells
were plated in triplicate and infected with each construct. Cellular viability was measured by
MTT assay for each cell line 48 hours after infection. Significant differences were seen in
both the BSC40 and GL261 cell lines but no such differences were observed in the A9F1 line
(*** = P<0.001, ** = P<0.01). Data are representative of three independent experiments.
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With INF-β

Without INF-β

Figure 12.
Syncytial formation in MEF cells (A) MEFs were pretreated with INF-β prior to viral infection
with each construct. In the presence of INF-β, viral infection does was not observed for any
construct. Data is representative of two independent experiments (B) MEFs were left
untreated prior to viral infection with each of the specified constructs. There was no
significant difference in spread observed in any fusion construct compared to vGFP. Data is
representative of three independent experiments. (C) GFP+ foci with and without treatment
of INF-β. While no infection is observed for any construct with treatment of INF-β, the
untreated viral infections reveals a less fusogenic phenotype than previously seen in other
cell lines. Images were taken at 4x magnification.
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Fusogenic MYXV shows decreased treatment efficacy in vivo
Having verified the efficacy of our constructs in vitro as well as the safety in the
context of INF responses, we next sought to test how this efficacy would translate to an
in vivo model. C57/B6 mice were injected subcutaneously with 400,000 A9F1 cells. Once
the tumor reached 25mm2, the mice were treated with the corresponding constructs at
1x107 FFU in 100 µL PBS. By day 31, all mock mice had reached euthanasia criteria. While
many of the mice treated with the fusogenic constructs showed a decrease in tumor
volume immediately after treatment, relapse was seen by day 25 in most mice. We
observed no improvement in efficacy, in terms of reduced tumor volume, in mice treated
with the fusogenic MYXV constructs compared to the vGFP treated group (Fig 13A). We
observed an inverse relationship between the viruses ability to form syncytia and in vivo
survival as evident by the decrease in efficacy of vGFP-NDV and vGFP-RSV compared to
vGFP-NFP, vGFP-BPV and vGFP (Fig 13B). To find a possible explanation for this
phenomenon treated tumors were harvested 24 hours after the final treatment. The
tumors were crushed, and a portion of the cellular suspension was used to infect BSC40
cells. We observed a significant decrease in viral titer in all four fusogenic MYXV
constructs, however the decrease in titer seen in vGFP-NDV and vGFP-RSV was the most
severe, with a decrease of three logs (Fig 13C, P < 0.01). It is important to note that we
observed syncytial formation in BSC40 from the virus recovered from the tumor. We next
sought to determine if the loss of titer was due to the clearance by the host organism’s
immune system or rather was a result of the syncytia formation itself. To test this theory,
NOD/SCID mice were injected subcutaneously with 400,000 A9F1 cells. After tumors
reached 25mm2 they were treated with the corresponding constructs at 1x107 FFU in 100
µL PBS. Unlike the C57/Bl6 mice, we did not observe a decreae in tumor volume after
treatment in the fusogenic constructs with the NOD SCID mice. A slight decrease was seen
initially in the vGFP cohort after treatment but this tumor eventually relapsed. Overall,
we again saw no improvement in efficacy with the fusogenic constructs in terms of tumor
volume (Fig 14A) or survival (Fig 14B). Furthermore, upon harvesting of the tumor to
analyze viral titer, we again observed again a decrease in viral titer observed in all four
constructs. Additionally, the decrease in titer seen in vGFP-NDV and vGFP-RSV were both
a full log lower than the titer collected for either the vGFP-NFP and vGFP-BPV treated
tumor. This suggests that the loss in viral titer is associated with syncytial formation rather
than clearance from the host immune system.
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Figure 13.
In vivo analysis of fusogenic MYXV efficacy. (A) A9F1 tumors were treated as indicated 14 days after
injection in C57/B6 mice. Mice were treated with 1x107 FFU of each construct. vGFP was the only
construct in which there was a noticeable decrease in the rate of tumor volume increase (n = 11 per
cohort). The vertical red line indicates the day after injection at which point all mock treated mice had
been euthanized. Data shown in representative of two independent experiments. (B) A9F1 tumors were
treated as indicated 14 days after injection. Mice were treated with 1x107 FFU of each construct. Both
the vGFP-NFP and vGFP-BPV cohorts had surviving animals, as did vGFP. Neither vGFP-NDV and vGFPRSV resulted in the survival of any animals as did the mock treatment (n = 11 per cohort). For the
purpose of this experiment, mice were euthanized once the tumor grew to 15mm in any direction. Data
is representative of two independent experiments. (C) A9F1 tumors were treated as indicated 14 days
after injection. Mice were injected with 1x107 FFU of each viral construct and tumors harvested 24
hours after the final injection. Tumors were then crushed and titer was analyzed by infection of BSC40
cells (vGFP, n = 6. All other constructs, n = 5) While all cells exhibited a significant decrease in titer
compared to the titer of the initial viral tier, this decrease was lowest in the vGFP-NDV and vGFP-RSV
cohorts (**= P < 0.01, *** = P < 0.001).
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Figure 14:
In vivo analysis of fusogenic MYXV efficacy in an immunologically compromised model. (A) A9F1
tumors were treated as indicated 14 days after injection in NOD/SCID mice. Mice were treated with
1x107 FFU of each construct. The addition of a fusogenic transgene did not result in a decrease in
tumor volume (n = 10 per cohort). The vertical red line indicates the day after injection at which
point all mock treated mice had been euthanized. Data shown is representative of two independent
experiments. (B) A9F1 tumors were treated as indicated 14 days after injection. Mice were treated
with 1x107 FFU of each construct. We observed no difference in survival rate for any of the treated
cohorts compared to the mock treatment (n = 10 per cohort). For the purpose of this experiment,
mice were euthanized once the tumor grew to 15mm in any direction. Data is representative of two
independent experiments. (C) A9F1 tumors were treated as indicated 14 days after injection. Mice
were injected with 1x107 FFU of each viral construct and tumors harvested 24 hours after the final
injection. Tumors were then crushed and the titer was analyzed by infection of BSC40 cells (vGFP, n
= 6. All other constructs, n = 5). Similar to the C57/B6 mice there was a significant decrease in
recovered viral titer compared to the initially injected titer. Likewise, this decreases was lowest in
the vGFP-NDV and vGFP-RSV cohorts (**= P < 0.01, *** = P < 0.001).
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Discussion
While the use of oncolytic viruses has shown efficacy as a novel form of cancer
therapy, there are still drawbacks associated with it. Foremost is the inability to spread in
vivo which can limit the overall efficacy of treatment. In light of this, OV has begun to
implement syncytia formation in order to increase both spread and cellular death in the
tumor microenvironment. Fusogenic viruses have previously been shown to increase
treatment efficacy and as such seemed a likely candidate to increase the oncolytic
potential of MYXV as well.
In order to test this hypothesis, we first had to generate fusogenic MYXV
constructs. Our constructs were generating using the transfection and transformation
protocols as described. Before implementing fusogenic MYXV constructs in a
physiologically relevant tumor model, we then sought to verify that we had created an
effective and functionally sound virus. We first verified that our newly created constructs
possessed the fusion proteins through western blot analysis and the presence of GFP+
foci. For the purpose of this study we applied the definition of syncytia in current
literature, a multinucleated cell body, to validate this phenotype in our constructs.
Interestingly while we were able to observe syncytial formation by GFP+ foci in two of our
constructs (vGFP-NDV and vGFP-RSV), we did not detect a signal for the myc tag in the
vGFP-RSV virus. This is a surprising result and could be related to the decrease in GFP
expression, which we only see in the vGFP-RSV construct. The cause of this phenomena
however remains unclear. Additionally, we were unable to observe similar syncytial
formation in the vGFP-NFP and vGFP-BPV constructs in terms of GFP+ images, however
both constructs did show the presence of the myc tag. This could be due to the differences
in activation and receptor specificity by which various fusion proteins induce fusion. To
further validate our constructs we examined them by confocal microscopy. We were able
to validate that the vGFP-NDV and vGFP-RSV constructs both caused syncytial formation,
based on the reconstruction of actin filament in the GFP+ cells as well as the inclusion of
multiple nuclei into the GFP+ area as outlined in Figure 10. Interestingly we also viewed a
syncytial phenotype in vGFP-NFP, though this construct seemed to exhibit a markedly less
obvious fusogenic phenotype in which the foci consists of several smaller syncytia, each
defined by multiple nuclei surrounded by actin filament, rather than a single large one.
As these immunofluorescent images fit the definition of syncytia which we were using for
the purpose of this study, we felt this validated the fusogenic nature of these constructs.
Additionally, we found that the addition of the novel fusion proteins did not alter the
replication rate of MYXV.
We next sought to analyze the added efficacy of the fusogenic MYXV constructs in
vitro to offer a rational for translation into an in vivo model. We first wished to analyze if
the addition of MYXV would increase viral spread. We found that, in both BSC40 and A9F1,
the addition of these novel transgenes significantly increased spread compared to the
non-fusogenic control. Unsurprisingly, this effect was only observed in the highly
fusogenic constructs of vGFP-NDV and vGFP-RSV. It is important to note that since the
fusion proteins are under a synthetic early/late promotor, these transgenes are expressed
very early in the viral replication cycle. In the vGFP construct, spread is limited to the rate
at which the virus can replicate but in the fusogenic constructs spread, in terms of cellular
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fusion, can occur much earlier and may explain this result. In addition to an increase in
spread we observed a significant increase in cellular death in two of the three cells lines
tested. This could be partially due to the cellular populations resistance to apoptosis
which is inherently higher in cancer cells compared to healthy cells. A higher resistance
to apoptosis may allow for the formation of syncytia that are large but stable, compared
to a syncytia that is losses cellular integrity as it increases in size. Interestingly in the GL261
cells, which exhibit severely heightened resistance to apoptosis we observed a significant
decrease in cell viability in all four fusogenic constructs compared to that of vGFP.
However, it is also important to mention that GL261 growth is dependent on special
proximity to neighboring cells and as such syncytial formation in vitro is less severe. The
exact mechanism by which syncytia induce apoptosis in different cell lines may warrant
further research as it seems to include more variables than spread alone. Finally, we
sought to examine if these novel constructs maintained the tumor specificity associated
with MYXV infection in an INF-β responsive cell line. From this study we were able to show
a complete lack of infection in any of the viral contructs in MEFs pretreated with INF-β.
Surprisingly, while analyzing the GFP+ foci of untreated MEFs the syncytial phenotype of
all four constructs was no longer visible. We also observe a decrease in spread of the
fusogenic constructs compared to vGFP in this regard. The reason for this difference in
phenotypes is unclear. This could potentially be due to a lack of the corresponding
receptors on neighboring cells which does not allow for fusion to occur. In addition, recent
work has shown that IFITM protein family is able to restrict syncytial formation in a variety
of viruses191. This protein family prevents cell-cell fusion through modulation of
membrane fluidity which makes the cell membrane resistant to fusion with either the
virus or a neighboring cell. It could be that MEFs exhibit naturally higher levels of this
protein family and thus suppress syncytial formation than do other cell lines which would
prove to be beneficial in terms of limiting syncytial formation in healthy cells outside the
tumor. However, due to the fact that we are using a virus which normally spread via cellcell contact rather than fusion, it is plausible that the IFITM proteins are preventing the
formation of syncytia in which case MYXV resorts to its natural means of spread. This
would explain the presence of GFP+ foci but no syncytia in each of our constructs
Knowing that we have increased efficacy and cellular death in vitro we next sought
to test these constructs in a more physiologically relevant model. However, in both the
C57/B6 and NOD/SCID mouse models we observed that the fusogenic constructs
increased tumor growth and decreased survival compared to vGFP. Interestingly this
decrease was inversely related to the constructs ability to form syncytia in vitro. In our
attempt to answer why this had occurred we found that in both models there was a
significant loss in viral titer associated with the fusogenic constructs but not seen in the
vGFP control. This led us to believe that the loss in titer was due to the rapid spread and
increased cytotoxicity of these constructs. We hypothesized that, in the case of vGFP-NDV
and vGFP-RSV, the increased rate of syncytial formation was leading to greatly increased
levels of lysis in the tumor microenvironment during treatment. This resulted in clearance
of both viral progeny and tumor antigen by the an early, rather than a late, immune
response and thus a decrease in the anti-tumor T-cell response we expected. Clearance
of the infectious virus after lysis resulted in complete relapse of the tumor. An additional
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hypothesis is that the fusion proteins are generating an antibody response to the protein
rather than the tumor. This response would result in the deactivation of the fusion
proteins and decrease the efficacy of treatment. This hypothesis seems likely given the
results of the NOD/SCID study. Given that NOD/SCID mice lack functioning B- and T- cells
we would expect to see the efficacy of the fusogenic constructs remain similar to that of
vGFP because the mice no longer have the ability to mount an antibody response towards
the F protein. It is also worth mentioning that this decrease in efficacy could be cell line
specific. As fusion proteins have specificity for particular receptors, it could be that the
A9F1 cell line does not express the binding partners for the particular F proteins used in
this study. If this proves to be true, it is possible that we could find a tumor model which
our constructs show efficacy in. It is also possible that as the tumor cells begin expressing
F protein and tumor infiltrating lymphocytes interact with the tumor cells as part of the
adaptive immune response, that fusion can occur between these two populations. As this
has not previously been shown to occur in the literature it is unclear how this would affect
the function of the lymphocytes, although it seems likely that this would hinder these
cells. Further tests will need to be performed in order to verify if these cells can be
included in the formation of syncytia.
The addition of fusion proteins is a novel strategy to enhance the oncolytic
potential of MYXV. This study represents one of the first to compare the oncolytic
potential of a several unique fusion proteins added to a single viral vector. Unfortunately,
while this therapy showed promising results in vitro they were unable to be translated
into our in vivo models. These results do point to a potential pitfall of fusogenic oncolytic
viruses, however. While the ability to increase spread is certainly beneficial, the question
is raised if a balance between spread and cytotoxicity must exist to maximize the rate of
infection before detection and elimination of the virus. Additionally, our in vitro data
suggests that the correlation between spread and cytotoxicity is more complex. Future
studies should look to address this correlation in the hopes of leveraging it for therapeutic
purposes.
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Materials and Methods
Cell lines and reagents
BSC40 cells (Cat# CRL-2761) and B16F10 cells (Cat# CRL-6475) were purchased
from American Type Culture Collection (ATCC, Manassas, VA, USA). U118, GL261 and T9
cells were purchased from Mediatech (Herndon, VA, USA). GL261 cells were purchased
from Mediatech (Herndon, VA, USA). Mouse embryonic fibroblasts were a kind gift from
Dr. Carl Atkinson. A9F1 cells were a kind gift from Dr. Mark Rubenstein. All cells were
cultured in DMEM (10% Fetal Bovine Serum + 1x Penicillin-Streptomycin-L-Glutamine
Corning (Oneonta, NY, USA). Temozolomide was purchased from Sigma (St. Louis, MO,
USA). Crizotinib was purchased from Selleckchem (Houston, TX, USA). Bevacizumab was
purchased from Genentech (San Francisco, CA, USA). Cell viability was measured using
the CellTiter-96 Non-Radioactive Cell Proliferation Assay, referred to as the MTT assay for
the purpose of this paper, (Promega, Madison, WI, USA). Caspase-3 activity was measured
using the commercially available Colorometric Caspase-3 Assay Kit (CASP3C, Sigma, St.
Louis, MO, USA) according to manufacturer protocol. Antibodies used for this study were
purchased from Santa Cruz Biotech (Santa Cruz, CA) and include: GAPDH (clone G-9, sc365062), Caspase-3 (clone 3C119, sc-70497), p-AKT (Clone 104A282, sc-52940), Actin
(clone I19) and c-myc (clone 9E10). For immunofluorescence: Hoechst 33342 (Cat# 62249)
(Thermofisher Scientific, Waltham, MA, USA) and Vectashield HardsetTM with TRITCPhalloidin (Cat#H-1600) (Vector Laboratories, Burlingame, CA, USA).
Generation of viral constructs
Viral constructs were generated by the following methodology. The pBluescriptM135/GFP/M136 used to generate these constructs was a kind gift from Dr. Grant
McFadden and has been fully described previously192. The plasmid was first digested at
the Nde1 and Pst1 restriction sites overnight. dsDNA encoding the transgenes of interest
were then ligated into the digested region using DNA ligase. Each inserted transgene was
placed under a synthetic early/late viral promoter. The ligated plasmid vector was than
transformed into DH5α E. coli overnight at 37°C. Colonies were then picked and tested
via colony PCR to ensure insertion of the transgene at the proper DNA template size. PCR
reactions were then run on a 0.1 percent agarose gel by electrophoresis. After verifying
the correct plasmid had been transformed, the selected colony was grown overnight in
Lysogeny broth (LB). The bacteria were then processed using the Qiagen plasmid miniprep
kit to amplify the plasmid. The processed plasmid was then used to make a glycerol stock
of the plasmid for future use. The rest of the processed plasmid was then transfected into
MYXV (strain Lausanne). For plasmid transfection, BSC40 cells were plated into six well
plates. Cells were then treated with Lipofectomine 3000 and the plasmid was added to
the well at a concentration of 5 µg. After 48 hours, the cells were infected with MYXV at
an MOI of 10. The plasmid was inserted into the viral genome at the m135r and m136r
reading frame by homologous recombination. After 24 hours, the cells were harvested
and the virus was subsequently purified by repeated infection and harvesting of GFP+
colonies until purity was established. Once the construct was purified, the virus was
amplified in 20 15cm plates of BSC40 cells. The cells were then infected at a high MOI and
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harvested after 48 hours. The cells were then subsequently freeze-thawed to release the
viral particles and purified using sucrose gradient purification.
Sequences of fusion proteins inserted into MYXV
To generate the fusogenic MYXV the following fusion proteins were inserted into
the pBluescript M135/GFP/M136 plasmid:
For vGFP-NDV, the fusion protein of NDV strain NDV/chicken/Egypt/Ismailia32/2016 the
following sequence was inserted.
ATCGCCCGGGAAAAATTGAAATTTTATTTTTTTTTTTTGGAATATAAATAACCATGGGCTCCAAACCTTCTACCAGGAT
CCCAGCACCTCTAATGCTCATCACTCGGATTATGCTGACATTGAGCTGCATTCGGTTGACAAACTCTCTTGACGGTAG
GCCCCTTGCAGCTGCAGGAATTGTAGTAACGGGAGATAAGGCAGTCAATGTATACACCTGGTCTCAGACAGGGTCA
ATCATAGTCAAGTTGCTCCCGAATATGCCCAGAGATAAGGAGGCATGTGCAAGAGCCCCATTGGAGGCATATAACA
GAACACTGACTACTCTGCTCACTCCTCTTGGTGATTCCATCCGCAAGATCCAAGGGTCTGTATCCACGTCCGGAGGAA
GGAGACAAAAACGTTTTATAGGTGCTGTTATTGGCAGTGTAGCTCTTGGAGTTGCAACAGCGGCACAGATAACAGC
AGCTGCGGCCCTGATACAAGCCAAACAGAATGCCGCCAACATCCTCCGGCTTAAGGAGAGCATTGCTGCAACCAAT
GAAGCTGTGCATGAAGTCACTGACGGATTATCACAACTATCAGTGGCAGTTGGGAAGATGCAGCAGTTTGTCAATG
ACCAGTTTAATAATACGGCGCGAGAATTGGACTGCATAAAAATCACGCAGCAGGTCGGTGTAGAACTCAACCTATA
CCTAACTGAATTAACTACAGTATTCGGGCCACAGATTACCTCCCCCGCATTAACTCAGCTGACCATCCAGGCACTTTA
TAATTTAGCTGGTGGCAATATGGACTACTTATTAACAAAGTTAGGTATAGGGAATAATCAACTCAGCTCATTAATTG
GTAGCGGCCTGATCACTGGTTACCCTATACTATATGACTCACATACTCAACTCTTGGGCATACAAGTAAATCTGCCCT
CAGTCGGGAACTTAAATAATATGCGTGCCACCTATTTGGAGACCTTATCTGTAAGTACAACCAAAGGATATGCCTCA
GCATTAGTCCCGAAAGTAGTGACACAAGTTGGTTCTGTGATAGAAGAGCTTGACACCTCATACTGTATAGAGTCCGA
TCTGGACTTATATTGTACTAGAATAGTGACATTCCCCATGTCCCCAGGTATTTATTCCTGTTTGAGTGGCAACACATCA
GCCTGCATGTATTCAAAGACTGAAGGCGCTCTCACTACGCCATATATGGCCCTTAGAGGCTCAGTTATTGCCAATTGT
AAGATAACAACGTGCAGATGTACAGACCCTCCTGGTATCATATCGCAAAATTATGGAGAAGCTGTATCCCTGATAGA
TAGACATTCTTGCAATGTCTTATCATTAGACGGAATAACTCTGAGGCTCAGTGGGGAATTTGATGCAACTTATCAAAA
GAACATCTCAATATTAGATTCTCAGGTCATCGTGACAGGCAATCTTGATATATCAACTGAACTTGGGAACGTCAACA
ATTCAATCAGCAATGCCTTGGATAGGTTGGCAGAAAGCAACAGCAAACTAGAAAAAGTCAATGTCAGACTAACTAG
CACATCCGCTCTCATTACCTATATTGTTCTAACTGTCATTTCCCTAATTTTCGGTGCACTTAGTCTGGCTTTAGCATGTT
ACCTGATGTACAAACAGAAGGCACAACAAAAGACCTTGCTATGGCTTGGGAATAATACCCTTGATCAGATGAGAGC
CACCACGAGAGCATACCCATACGATGTTCCAGATTACGCTTAAGAATTCATCG

For vGFP-RSV, the fusion protein of RSV strain A2 long the following sequence was
inserted.
ATCGCCCGGGAAAAATTGAAATTTTATTTTTTTTTTTTGGAATATAAATAACCATGGAGCTGCTGATCCTGAAGGCCA
ACGCCATCACCACCATCCTGACCGCGGTGACCTTCTGCTTCGCCTCTGGCCAGAACATCACTGAGGAGTTCTACCAGA
GCACTTGTTCCGCTGTGAGCAAGGGCTACCTGAGCGCCCTGAGGACCGGTTGGTACACCAGCGTGATCACCATCGA
GCTGAGCAACATCAAGAAGAACAAGTGCAACGGCACCGACGCCAAGGTGAAGCTGATCAAGCAAGAGCTGGACAA
GTACAAGAACGCCGTGACCGAGCTGCAACTGCTGATGCAGTCGACTCAAGCCACCAACAACAGAGCCCGCAGCGAG
CTGCCCCGCTTGATGAACTACACCCTGAACAACGCCAAGAAGACCAACGTGACCCTGTCCAAGAAGAGGAAGCGCC
GCTTGCTGGGCTTCCTGCTGGGCGTGGGCTCCGCCATTGCCAGTGGCGTGGCCGTGTCCAAGGTGCTGCACCTGGA
GGGCGAGGTGAACAAGATCAAGAGTGCCCTGCTGTCCACTAACAAGGCCGTGGTGAGCCTGAGCAACGGCGTGAG
TGTGCTGACTAGCAAGGTGCTGGACCTGAAGAACTACATCGACAAGCAATTGCTGCCCATCGTGAACAAGCAGTCCT
GTAGCATCTCCAACATCGAGACTGTGATCGAGTTCCAGCAGAAGAACAACCGCCTGCTGGAAATCACCCGAGAGTT
CAGTGTGAACGCTGGCGTGACCACTCCTGTCTCCACCTACATGCTGACCAACAGCGAGCTGCTGAGCCTGAGCAACG
ACATGCCCATCACCAACGACCAGAAGAAGCTTATGTCCAACAACGTGCAGATCGTGAGGCAGCAGAGCTACTCCAT
CATGAGCATCATCAAGGAGGAGGTGCTGGCCTATGTGGTGCAGCTGCCCCTGTACGGCGTCATCGATACCCCTTGCT
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GGAAGCTGCACACCAGCCCCCTGTGCACCACCAACACCAAGGAGGGCAGCAACATCTGCCTGACCCGGACCGACCG
CGGCTGGTACTGTGACAACGCTGGCTCGGTGAGCTTCTTCCCTCAAGCTGAAACCTGCAAGGTCCAGAGCAACAGA
GTGTTCTGTGACACCATGAACTCCCTGACCCTGCCCTCCGAGGTGAACCTGTGCAACGTGGATATCTTCAACCCCAAG
TATGACTGCAAGATCATGACCTCCAAGACCGATGTCTCGAGCTCCGTGATCACCAGCCTGGGCGCCATCGTGTCCTG
CTATGGCAAGACCAAGTGCACCGCCAGCAACAAGAACCGGGGCATCATCAAGACCTTCAGCAATGGGTGCGACTAC
GTTTCGAACAAGGGCGTGGACACTGTGTCCGTGGGCAACACCCTGTACTACGTGAACAAGCAAGAGGGCAAGAGC
CTGTATGTGAAGGGCGAGCCCATCATCAACTTCTACGACCCCCTGGTGTTCCCCTCCGACGAATTTGACGCCTCCATT
AGCCAAGTCAACGAGAAGATCAACCAGAGCCTGGCCTTCATCCGCAAGTCCGACGAGCTGCTGCACAACGTCAACG
CTGGCAAGAGCACCACCAACATCATGATCACCACCATCATCATCGTGATCATCGTGATCCTGCTGAGCCTGATCGCC
GTGGGCCTGCTGCTGTACTGTAAGGCCCGGAGCACTCCCGTGACCCTGAGCAAGGACCAGCTGAGCGGCATCAACA
ACATCGCCTTCAGCAACTACCCATACGATGTTCCAGATTACGCTTGAGAATTCATCG

For vGFP-NFP, the fusion protein of the Nipha virus Malaysia strain the following
sequence was inserted.
ATCGCCCGGGAAAAATTGAAATTTTATTTTTTTTTTTTGGAATATAAATAACCATGGTAGTTATACTTGACAAGAGAT
GTTATTGTAATCTTTTAATATTGATTTTGATGATCTCGGAGTGTAGTGTTGGGATTCTACATTATGAGAAATTGAGTA
AAATTGGACTTGTCAAAGGAGTAACAAGAAAATACAAGATTAAAAGCAATCCTCTCACAAAAGACATTGTTATAAAA
ATGATTCCGAATGTGTCGAACATGTCTCAGTGCACAGGGAGTGTCATGGAAAATTATAAAACACGATTAAACGGTAT
CTTAACACCTATAAAGGGAGCGTTAGAGATCTACAAAAACAACACTCATGACCTTGTCGGTGATGTGAGATTAGCCG
GAGTTATAATGGCAGGAGTTGCTATTGGGATTGCAACCGCAGCTCAAATCACTGCAGGTGTAGCACTATATGAGGC
AATGAAGAATGCTGACAACATCAACAAACTCAAAAGCAGCATTGAATCAACTAATGAAGCTGTCGTTAAACTTCAAG
AGACTGCAGAAAAGACAGTCTATGTGCTGACTGCTCTACAGGATTACATTAATACTAATTTAGTACCGACAATTGAC
AAGATAAGCTGCAAACAGACAGAACTCTCACTAGATCTGGCATTATCAAAGTACCTCTCTGATTTGCTTTTTGTATTT
GGCCCCAACCTTCAAGACCCAGTTTCTAATTCAATGACTATACAGGCTATATCTCAGGCATTCGGTGGAAATTATGAA
ACACTGCTAAGAACATTGGGTTACGCTACAGAAGACTTTGATGATCTTCTAGAAAGTGACAGCATAACAGGTCAAAT
CATCTATGTTGATCTAAGTAGCTACTATATAATTGTCAGGGTTTATTTTCCTATTCTGACTGAAATTCAACAGGCCTAT
ATCCAAGAGTTGTTACCAGTGAGCTTCAACAATGATAATTCAGAATGGATCAGTATTGTCCCAAATTTCATATTGGTA
AGGAATACATTAATATCAAATATAGAGATTGGATTTTGCCTAATTACAAAGAGGAGCGTGATCTGCAACCAAGATTA
TGCCACACCTACGACCAACAACATGAGAGAATGTTTAACGGGATCGACTGAGAAGTGTCCTCGAGAGCTGGTTGTTT
CATCACATGTTCCCAGATTTGCACTATCTAACGGGGTTCTGTTTGCCAATTGCATAAGTGTTACATGTCAGTGTCAAA
CAACAGGCAGGGCAATCTCACAATCAGGAGAACAAACTCTGCTGATGATTGACAACACCACCTGTCCTACAGCCGTA
CTCGGTAATGTGATTATCAGCTTAGGGAAATATCTGGGGTCAGTAAATTATAATTCTGAAGGCATTGCTATCGGTCC
TCCAGTCTTTACAGATAAAGTTGATATATCAAGTCAGATATCCAGCATGAATCAGTCCTTACAACAGTCTAAGGACTA
TATCAAAGAGGCTCAACGACTCCTTGATACTGTTAATCCATCATTAATAAGCATGTTGTCTATGATCATACTGTATGTA
TTATCGATCGCATCGTTGTGTATAGGGTTGATTACATTTATCAGTTTTATCATTGTTGAGAAAAAGAGAAACACCTAC
AGCAGATTAGAGGATAGGAGAGTCAGACCTACAAGCAGTGGGGATCTCTACTACATTGGGACATACCCATACGATG
TTCCAGATTACGCTTAGGAATTCACTG

For vGFP-BPV, the fusion protein of the Bovine parainfluenza virus strain TVMDL60 the
following sequence was inserted.
ATCGCCCGGGAAAAATTGAAATTTTATTTTTTTTTTTTGGAATATAAATAACCATGATCATCACAGCCATAATTGTAGC
CATATTACTAATACCCCTATCATTCTGTCAAATAGACATAGCAAAACTGCAACGTGTAGGTGTATTAGTCAGTAATCC
CAAAGGTATGAAGATTTCACAAAATTTTGAGACAAGATACCTAATACTGAGTCTCATACCCAAAATAGAAAACTCAC
ACTCATGTGGGGACCAACAGATAAACCAATATAAGAAGTTATTGGATAGATTGATAATTCCTCTATATGATGGATTA
AAATTACAAAAGGATGTGATAGTAGTAAATCATGAAACTCACAATAATACTGGCCTTAGGACGAAACGATTCTTTGG
AGAGATAATCGGAACTATTGCGATAGGGATAGCCACATCAGCGCAAATCACTGCAGCAGTCGCCCTTGTCGAGGCC
AAACAGGCAAGATCAGACATAGAAAAACTCAAAGAAGCTGTAAGAGACACAAATAAGGCAGTACAATCAATTCAAA
GTTCTGTAGGTAATCTAATTGTTGCAGTTAAATCAATCCAAGATTATGTCAACAATGAAATTGTACCTTCAATTACAA
GATTAGGTTGTGAGGCAGCAGGATTACAACTAGGAATTGCATTGACACAACATTACTCAGAATTAACAAATATATTT
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GGTGATAATATTGGGACACTAAAAGAAAAGGGGGTAAAACTACAAGGGATAGCATCACTATACCACACAAATATAA
CAGAAATATTTACTACTTCGACAGTTGACCAATATGATATTTATGATCTACTATTCACTGAGTCAATCAAGATGAGAG
TGATAGATGTTGATTTGAGTGATTACTCAATCACTCTTCAAGTTAGACTTCCTTTGTTAACTAAACTATCAAATACTCA
AATCTATAAGGTGGATTCTATATCATACAATATCCAAGGCAAGGAGTGGTATATTCCTCTTCCCAGCCATATCATGAC
TAAAGGAGCTTTTCTAGGCGGTGCTGATATTAAAGAATGCATAGAGGCATTCAGCAGTTATATATGTCCTTCTGATCC
AGGTTTTATCTTAAATCATGAGATAGAGAATTGTTTATCAGGTAATATAACACAGTGTCCTAAGACTGTTGTTACATC
AGATGTGGTACCACGATATGCATTTGTGAATGGTGGATTAATTGCAAACTGTATAACAACAACATGCACATGCAATG
GAATCGACAATAGAATCAATCAATCACCTGATCAGGGAATAAAAATCATAACATATAAAGAATGTCAGGTAATCGGT
ATAAATGGAATGTTATTCAATACCAATAGAGAGGGAACATTAGCAACCTATACATTTGATAACATCATATTAAATAAC
TCTGTTGCACTTAATCCAATTGACATATCTATGGAACTCAACAAGGCAAAATTGGAACTGGAAGAATCGAAGGAATG
GATAAAAAAATCAAATCACAAACTGGATTCTGTTGGAAGTTGGTATCAATCTAGTGCAACAGTCACCATAATCATAG
TGATGATAGTAATCTTATTCATAATCAATATAATAATTATTATAATCATAATCAAATACCATAGAATCCAAGGGGGAA
AACAGGAAGACAAAAACAATGAACCGTATGTACTAACAAGTAGAAAATACCCATACGATGTTCCAGATTACGCTTAA
GAATTCACTG

GBM SOC treatment protocol
Cells were first plated into the indicated plate at half confluency. Twelve hours
prior to infection, cells were pretreated with 1 Gy of radiation. Cells were then infected
with virus at the corresponding MOI. At one hour after infection the inoculum was
removed and was replaced with media containing TMZ at a dosage of 10 mg/kg. The data
analysis for the experiment was then performed as indicated. This procedure it outlined
in figure 15A.
Initial infection assay
Cells were plated onto a 12 well plate to confluency. The cells were then
pretreated with the GBM SOC treatment strategy described above and infected with the
corresponding MOI. After 12 hours the media was removed, and the cells were washed
with sterile 1% PBS three times. Cells were then harvested from the plate and pelleted at
2500 RPM for five minutes by centrifugation. The supernatant was discarded, and the cell
pellet were resuspended in 2% Paraformaldehyde (PFA). The samples were then analyzed
via flow cytometry for percentage of GFP+ cells. The data was analyzed using flowjo.
Single step growth curve
The cell line of interest was plated onto a 12 well plate. The cells were then
infected at the indicated MOI. After one hour, the inoculum was removed, the cells were
washed with sterile 1% PBS and fresh media was added to the well. The cells were
harvested at 3, 6, 12, 24, 48 and 72 hours after the infection. To harvest cells, the media
was removed, and cells were pipetted off the well. Cells were then spun at 2500 RPM for
five minutes by centrifugation and the supernatant was discarded. Samples were stored
at -80°C. Samples were then titerd by repeated cycles of sonication followed by freezing
with liquid nitrogen. The cell pellets were then resuspended and 2 µL of sample was
diluted into 2 mL of media. The solution was further diluted from 10-3 to 10-8 in media.
From each dilution, 1 mL was added to BSC40 cells plated into a 12 well plate in duplicate.
After 48 hours, the GFP+ foci were counted in order to determine the viral titer of each
sample.
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Foci forming assay
The indicated cell lines were plated into six well plates in duplicate. Cells were
then infected with the indicated MOIs. After one hour the inoculating media was removed
and cells were washed with sterile 1% PBS three times before fresh media was added. At
24-hour intervals images of singular GFP+ foci were taken by fluorescent microscopy. Foci
area was then measured using ImageJ software. To measure foci image, individual foci
were traced in ImageJ and measured using the area measurement command. These
values were then averaged for each timepoint and graphed accordingly.
MTT assay
Cells were plated to confluency in a 96 well plate as triplicates and infected with
the indicated MOI. At 24-hour intervals after infection, cells were treated with 10 µL of
reaction solution containing the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyetraolium
bromide) compound. The reaction was then stored in the dark at 37°C until the MTT
compound was fully converted to formazan, indicated by the presence of purple
precipitate. Once the conversion was completed, 100 µL of solubilization/stop solution
was added to lyse the cells and release the formazan product. The plate was then kept
from light and absorbance was measured at a wavelength of 595 nm using an Epoch 2
microplate reader. Viability was determined by averaging the readings of each triplicate
as a percentage of mock.
Western blot
Cells were first plated into six well plates with media serum free media. Cells were
then infected with the indicated MOI. After one hour, the inoculating media was removed
and fresh serum free media was added. Cells were then harvested 24 hours after infection
and prepped for western blot. Western blot preparation was done as follows. Cells were
pelleted by centrifugation at 2500 RPM for 5 minutes after which the supernatant was
removed. The pellet was then resuspended in 95 µL of Laemmli buffer and 5 µL of βmercaptoethanol. The samples were then heated at 99°C for five minutes and stored at 20°C for long term storage. Samples were then run by western blot using the following
protocol. Acrylamide gels were loaded with 5 µL of sample and PageRuler Prestained
protein ladder. The electrophoresis box was filled with running ladder and the gels were
run at 20 mA per gel for two hours. Once the run was complete the gel was removed and
transferred unto PVDF paper activated with methanol. Gels were transferred at 0.04 mA
for 30 minutes while in transfer buffer. After transfer, PVDF was rocked in TBS-T
containing primary antibody (at a concentration of 1:1000) and blocking agent overnight
at 4°C. On the second day, PVDF was removed from the primary antibody solution and
rinsed twice with TBS-T for 15 minutes. The PVDF was then incubated in the TBS-T
containing secondary antibody (at a concentration of 1:5000) and blocking agent for two
hours at 4°C. After two hours, the PVDF was rinsed twice with TBS-T for 15 minutes. PVDF
was the treated with photoreactive reagents for three minutes prior to exposure. Films
were processed in developer in dark room immediately after treatment with the
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photoreactive reagents. For the purpose of publication, films were scanned and color was
inverted using Microsoft paint.
MXYV stability assay
To test viral stability over time, 5 µL aliquots were incubated at the corresponding
temperatures for 0, 3, 6, 9, 12, 24, 48, 72 and 96 hours. At each time point, the aliquoted
samples were removed and stored at -80°C until samples were processed. After all
samples were collected, samples were titered onto BSC40 cells plated in a 12 well plate.
To titer viral samples, 2 µL were added to 2 mL of media. This stock solution was
subsequently diluted to yield a dilution series of 10-3 to 10-8. From each dilution, 1 mL was
added to BSC40 cells in duplicate. After 48 hours, viral titer was determined by counting
the number of GFP+ foci in each sample.
Verification of viral transport by osmotic pump
Prior to filling of the bladder, the pump was assembled and primed overnight in
water at 37°C per manufacturer instructions. The bladder of the pump was then filled
with 100 µL of solution containing sterile 1% PBS, bromophenol blue and MYXV at a
concentration of 1x107 FFU either with or without temozolomide as indicated. The pump
was then placed in a beaker of water and the tube was inserted into a collection tube
containing 1 mL sterile 1% PBS. As it took several hours for the liquid in the pump to reach
the collection tube, we set the this point as our initial timepoint. At each indicated
timepoint (0, 3, 6, 9, 12, 24, 48, 72 and 96 hours after pumping) the collection tube was
removed and replaced, samples were stored at -80°C. The samples were then thawed via
sonication and 2 µL of sample was added to 2 mL of media. This stock solution was diluted
further to yield a dilution series of 10-3 to 10-8. However, once we observed no GFP+ foci
we repeated this study with a dilution series ranging from 10-1 to 10-3 to detect lower
levels of viral particles. We next repeated the assay by harvesting sample from the tubing
and the bladder itself. To collect these samples, a tube was set up for each indicated
timepoint. At the time of harvesting we flushed sterile 1% PBS through the tubing or the
bladder in order to remove the residual liquid and any viral particles which had adhered
to the surface of either component at the corresponding timepoint. We then titered the
samples as described above.
Immunofluorescent staining
Cells were first plated onto 15 mm glass coverslips and infected with virus at the
indicated MOI. After 24 hours, the cells were stained as follows. The inoculating media
was removed and the cells were rinsed twice with 1 mL of sterile 1% PBS. Cells were then
fixed with 2% PFA for 15 minutes. The coverslips were then rinsed three times with PBS.
The coverslips were removed from the plate and dried. Onto glass slides, 25 µL of
VECTASHIELD mounting media with phalloidin and Hoeschst stain was pipetted and
coverslips were placed cell side down onto the slides. The slides were incubated for 30
minutes at room temperature and stored at 4°C. Samples were then imaged using the
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Olympus FV10i laser scanning confocal microscope. Images were taken at a magnification
of 40x.
MEF Interferon Beta treatment
MEFs were plated into six well plates in duplicate. Twelve hours prior to infection,
cells were pretreated with 5 µL of INF-β or left untreated as a control. The cells were then
infected with virus at the indicated MOI. One hour after infection, the inoculating media
was removed and fresh media was added to the cells. At 24 hour intervals after infection
images of singular GFP+ foci were taken by fluorescent microscopy. Foci area was then
measured using ImageJ software. To measure foci image, individual foci were traced in
ImageJ and measured using the area measurement command. These values were then
averaged for each timepoint and graphed accordingly.
GBM patient samples
GBM patient samples were collected surgically from patients diagnosed with GBM
according to the Response Assessment in Neuro-Oncology Criteria. Patients were
evaluated based on magnetic resonance imaging (MRI), as well as clinical and pathological
examination. Patients who received neoadjuvant chemotherapy and/or radiotherapy
prior to surgery were excluded. GBM samples from 3 male patients (confirmed by
histopathological examination by a pathologist) were analyzed. All tissue was collected
and handled according to procedures approved by the MUSC Institutional Review Board.
Slice cultures were prepared from fresh human GBM specimens. Following
surgical excision, tissue was transported to the laboratory in minimal essential medium
(MEM; Invitrogen, Carlsbad, CA, USA). Tissue was prepared using the standard Stoppini
Slice Culture Technique at a thickness of 250 µm193. The slices were then transferred onto
membrane culture inserts (Millipore, Burlington, MA, USA) in 6-well plates at a maximum
of three slices per insert. Slices were cultured in MEM (Gibco, Waltham, MA, USA),
supplemented with 25% Hank’s Balanced Salt Solution (with Ca and Mg; Gibco, Waltham,
MA, USA), 20% Horse serum (Gibco, Waltham, MA, USA), 2 mM l-glutamine (Braun,
Bethlehem, PA, USA), 0.5% glucose, and 1% penicillin/streptomycin (Sigma, St. Louis, MO,
USA). Slices were then cultured on a liquid/air interface in a humidified incubator at 37°C
and 5% CO2, and the medium was changed three times a week.
In vivo tumor studies
C57/B6 (Charles River Laboratories, Raleigh, NC, USA) or NOD/Scid (The Jackson
Laboratory, Bar Harbor, ME, USA), six to eight weeks of age, were injected subcutaneously
(SQ) with 4x105 A9F1 cells in 50 µL of sterile 1% PBS. Viral treatment consisted of three
intratumoral (IT) injections of each viral construct (vGFP, vGFP-NDV, vGFP-RSV, vGFP-NFP,
vGFP-BPV) over the span of five days, once the tumor had grown to 25 mm2 (Fig 15B). For
survival studies, tumor size was monitored with calibers until the tumor reached 15 mm
in any direction at which point the mouse was euthanized. Euthanasia consisted of CO2
fixation followed by cervical dislocation. All experiments were conducted in accordance
with the Medical University of South Carolina Institutional Animal Care and Use
Committee.
51

Analysis of in vivo viral titer
For analysis of intertumoral viral titer the tumor was excised 24 hours after the
third treatment. The tumor was then transferred to a 40 µm mesh filter and mechanically
separated into a single cell suspension in sterile 1% PBS. From this cell suspension, 2 µL
was diluted into 2 mL of fresh media. The solution was further diluted to create a dilution
series which ranged from 10-3 to 10-8. From each diluted in the series, 1 mL was added
onto BSC40 cells. After 48 hours, the number of GFP+ foci were counted at each dilution
in order to determine viral titer. All experiments were conducted in accordance with the
Medical University of South Carolina Institutional Animal Care and Use Committee.
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Figure 15: Schematic of experimental designs. (A) Timeline for treatment in GBM
SOC study. (B). Timeline for treatment in in vivo fusogenic experimental model.
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Conclusion and Study Significance
Oncolytic virotherapy is gaining ground as an effective cancer therapeutic.
However, like most treatment modalities there still exists a need to improve efficacy. As
such studies which look into novel ways in which to increase treatment efficacy old
considerable importance. This study sought to improve efficacy through the combination
a current oncolytic virus, MYXV, with two novel therapeutic enhancements.
We first sought to explore the possibility of combining MYXV with the current SOC
for GBM. Due to its unique physiological characteristics, GBM represents a unique
therapeutic challenge. This study is the first to show that by combining SOC for GBM with
an unaltered MYXV both spread, and cytotoxicity were increased. We hypothesize that in
an in vivo model this will translate into greatly improved efficacy. This study also is the
first to look at the potential of delivering an oncolytic virus through an osmotic pump as
a therapeutic tool. While it is unfortunate that we could not recover infectious virus from
our pump system, we still believe that with proper modifications this can prove to be an
effective means of delivery for our therapy.
Secondly, we sought to improve MYXV treatment by addressing one of its biggest
pitfalls: poor spread in vivo. By introducing a novel set of fusion proteins, we hoped to
impart to ability to fuse cells into syncytia onto MYXV as a means to increase efficacy. This
study represents one of the few which has looked at the fusion protein of multiple viruses.
While we were able to show efficacy in vitro, these results did not translate to an
increased efficacy in vivo. While the exact reason for this decrease in efficacy is unclear,
we hypothesize that it is related to the decrease in viral titer recovered from the tumor.
This study demonstrates that MYXV is an excellent candidate to combine with
novel therapeutic strategies. We hope that this study lays the foundation for advances
which such therapeutics. Especially important is an emphasis on understanding the
fundamental mechanisms that allow for these forms of therapy to be translated across a
wide variety of tumor models.
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